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Type 1 diabetes (T1D) is a disease in which the body immune system attacks
the β-cells. As a result, very little, or no insulin is released to control the level of
glucose in the blood. Our research investigates whether groups of patients at higher
risk for developing T1D complications can be identified by integrating demographic,
clinical and genetic data. Regarding this purpose, we explore two methods including
Generalized Low Rank Models (GLRM) and Similarity Network Fusion (SNF) to
investigate our T1D dataset and to determine groups of patients at higher risk of
developing complications related to T1D.
By applying the stated methods, we have identified groups of patients suffering
from nerve damage, high blood pressure, dyslipidemia, and thyroid diseases. This
result could be used as the basis to achieve a predictive model that could allow
patients and health-care providers to take preemptive steps to reduce the risk of
developing T1D related complications.
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Diabetes mellitus type 1 also known as type 1 diabetes (T1D) is a disease in which
the body immune system attacks the β-cells. As a result, very little, or no insulin
is released to control the level of glucose in the blood. Thus the amount of glucose
obtained from foods will be built up in the body instead of being used for energy.
This research investigates whether groups of patients at a higher risk for develop-
ing complications or secondary disease related to T1D can be identified by integrating
demographic, clinical and genetic data. We have a T1D dataset which contains 239
features concerning demographic, clinical and genetic factors from 196 patients (de-
tails are available in Section 1.4). We will explore two methods including Generalized
Low Rank Modelling (GLRM) [1] and Similarity Network Fusion (SNF) [2] to analyze
this dataset.
As a result of our research, we have taken first steps to identify groups of patients
at higher risk of developing T1D complications. This results could be taken as the
basis to develop a predictive model that could allow patients and health-care providers
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to take preemptive steps to reduce the risk of developing T1D related complications
based on each patient characteristics
To sum up, we have a heterogeneous dataset that contains demographic, clinical
and genetic data from T1D patients. Our research goal is to determine groups of
patients at higher risk of developing complications or secondary disease related to
T1D by analyzing this dataset.
1.1 Biological Background
T1D is not a preventable disease and is not related to eating an excessive amount
of sugar. Scientists could not determine any particular agent for the cause of T1D
yet [3]. Many factors may contribute to T1D, including genetic susceptibility and
exposure to specific antigens. Hence, T1D is considered a “complex disease” which
a combination of numerous risk factors may lead to it. T1D occurs when the body’s
immune system destroys the β-cells in the pancreas [4, 5]. T1D is a polygenic disorder,
with about 50 loci so far known to influence this disease susceptibility [6]. In this
research we investigate following complications related to T1D.
Thyroid Disease: Thyroid disease affects the thyroid gland which controls various
metabolic processes in the body. Thyroid dysfunction in patients with T1D is
two - to three fold higher than in the general population [7, 8].
Dyslipidemia: Dyslipidemia is an abnormal amount of lipids in the blood. People
with T1D have increased rates of vascular disease in which dyslipidemia is a
major risk factor [9].
2
High Blood Pressure: High blood pressure is common in people with diabetes
and about 25% of people with T1D develop high blood pressure at some stage.
Having diabetes and high blood pressure together, increases risk of other health
problems [10].
Nerve Damage: Nerve damage can occur in people with T1D which is called Dia-
betic neuropathy. Depending on the types of nerve damage it causes different
symptoms. More than 50% of all diabetics patients suffer from some types of
nerve damage [11].
Retinopathy: Retinopathy is the impair to the retina of eyes, which may leads to
vision problems. During the first two decades of T1D disease, nearly all patients
suffers from diabetic retinopathy [12].
Diabetic ketoacidosis: Diabetic ketoacidosis occurs when the body produces high
levels of blood acids called ketones. Diabetic ketoacidosis (DKA) are common
serious complications of T1D [13].
Hyperglycemia: Hyperglycemia is a condition in which an excessive amount of
glucose is in the blood plasma. Low insulin levels in T1D patients cause hyper-
glycemia [14].
Hypoglycemia: Hypoglycemia is when blood sugar decreases to below normal levels
in the blood. It is a common and dangerous occurrence with T1D patients [15].
Anxiety and Depression: Mental health problems are frequent in youth with T1D,
and they are at an increased risk of mental health conditions, such as anxiety,
eating and behavioral disorders, as well as depressive symptoms [16].
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1.2 Related Works
We review related research to this study from three different approaches: 1- Type 1
Diabetes genetics, 2- Heterogeneous data analyzing challenges, 3- Patients subgroup
discovery strategies.
1.2.1 Type 1 Diabetes Genetics
There are many papers published in the literature about T1D. T1D is one of the most
common chronic diseases of childhood [17]. Genetic studies of T1D have identified
50 loci (susceptibility regions) that affect risk of T1D [6, 18, 19]. Atkinson et al. [20]
released a survey that reviews current flow in epidemiology, pathology, diagnosis, and
treatment of T1D, and its prospects for an improved future for individuals dealing
with this disorder. Davies et al. [21] searched the human genome for genes that
influence T1D. Additionally, Barrot et al. [22] reported findings of a genome-wide
association study of T1D, combined in a meta-analysis. Roizen et al. [23] compared
variants associated with increased risk for T1D with those variants identified in other
autoimmune diseases and revealed genetic overlap between T1D and other autoim-
mune diseases.
1.2.2 Heterogeneous Data Challenges
Integrating data from different sources such as clinical, environmental, and demo-
graphic data with genomic data is an ongoing part of current research in genomics.
In our research, we have chosen to use two mentioned approaches (GLRM and SNF)
which are able to handle heterogeneous data. However, we acknowledge that there
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are several efforts underway to deal with heterogeneous data. For example, Hamid et
al. [24] proposed a conceptual framework for integrating data as well as a review of
current approaches for combining genomic data. As another example, Ren et al. [25]
evaluated the possible challenges in the integrative analysis of the heterogeneous dis-
ease data types. They proposed a computational method (named iBFE) based on
a feature extraction perspective. They showed that iBFE could recognize disease
subtypes in genomic data.
1.2.3 Patients Subgroup Discovery
Diagnosing and defining subtypes is a difficult challenge for complex diseases. Higdon
et al. [26] described how different disease subtypes could be identified through the
combination of clinical and multi-omics data. In the article, they clustered various
types of omics data and then, the results were integrated with clinical data to identify
disease subtypes. They applied this method to Autism Spectrum Disorder (ASD) to
facilitate subtype identification.
1.2.3.1 Network Approaches
A computational framework is presented by Zhang et al. [27] to stratify a biological
network into function-specific network layers, which transform the network analysis
from gene level to the functional level by integrating expression data, the gene/protein
network and gene ontology information.
A large scale of studies in complex disease is classifying patients based on their
genomic mutations, but these mutations are rarely shared across patients for some
diseases. Zhong et al. [28] used network-based stratification approaches on thirteen
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major cancer types to classify tumours based on exome-level mutations.
Beforehand, the most common approach to integrative data analyzing was a sep-
arate clustering followed by a manual integration. Shen et al. [29] developed a joint
latent variable model for integrative clustering (called iCluster). They could identify
subtypes in breast cancer and lung cancer, characterized by concordant DNA copy
number changes and gene expression using the iCluster algorithm. Kim et al. [30]
proposed a method to improve feature selection on iCluster factor model using prior
knowledge of inter-omics regulatory flows.
Hillenmeyer et al. [31] used a combination of an algorithm for weighted-edge mod-
ule searching and a probabilistic interaction network in order to explain a method for
designating genes with strong associations to the phenotype.
Cho et al. [32] showed how networks could be used to represent clinical data
such as genotype and gene expression to distinguish dysregulated pathways and to
understand the connections between genotype and phenotype, and to explain disease
heterogeneity. Their article showed how to analyze complex disease using similarity
network fusions since genetic variations in affected individuals might be different.
Wang et al. [2] used similarity network fusions for disease data obtained from a group
of patients. Yang et al. [33] proposed an integrative method based on Similarity
Network Fusion (SNF), named ndmaSNF (network diffusion model assisted SNF).
This method can be used for cancer subtype discovery with making use of somatic
mutation data and other discrete data.
Wang et al. [34] proposed a network-based approach for the integrative analysis
of heterogeneous omics data. They represented a network-based solution in which
each type of data is treated independently and tested the method on the subtypes
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identification of a brain tumor.
1.2.3.2 Machine Learning Approaches
Speicher et al. [35] extended multiple kernel learning for dimensionality reduction.
They could identify biologically meaningful subgroups for five different cancer types.
Schuler et al. [36] applied Generalized Low Rank Modelling presented by Udell et
al. [1] to discover phenotypes in two datasets of patient information related to two
different diseases. The method is used to overcome barriers such as missing data, data
sparsity, and data heterogeneity in input data. As shown in this paper, the result
of GLRM method is remarkably different in comparison to other machine learning
methods in applications of discovering patient phenotypes.
Young et al. [37] used unsupervised deep learning to learn the hierarchical struc-
ture of cancer gene expression data. They showed that a deep learning model can
be trained to represent biologically and clinically important concepts of cancer genes.
Lasko et al. [38] introduced new deep learning methods used for phenotype discovery
in clinical data.
Wei et al. [39] tested Support Vector Machine (SVM) on three large-scale GWAS
dataset generated on the Affymetrix genotyping platform for type 1 diabetes (T1D)
and demonstrated a risk assessment for this disorder.
1.3 Research Question
This research is an interdisciplinary study across computer science, molecular biology,
and medicine. The aim of conducting this research is to improve knowledge regarding
7
complications associated with T1D and its risk factors and, to eventually achieve an
efficient, trusted preemptive strategy for T1D.
Our research is distinct from previous research by three different aspects: 1- We
have a unique dataset from T1D patients that comprise demographic, clinical and
genetic data, from both diagnosis stage and patients current stage. 2- We are using
two state-of-the-art methods to identify patient subgroups. 3- We include several T1D
complications instead of focusing on a single complication. To investigate our T1D
dataset, we apply two methods namely Generalized Low Ranks Modelling (GLRM),
and Similarity Network Fusion (SNF). GLRM advantages are handling missing values
and compressing data. SNF profits from capturing both shared and complementary
information in the fused network. Our results can be used to identify patients at
higher risk of developing T1D complications and could be taken as the basis to create
a predictive model of developing T1D complications.
1.4 Dataset Overview
Our dataset is collected from a cohort study by Newhook et al. [40] regarding the
incidence of childhood T1D in children aged 0-14 years who were diagnosed with T1D
on the Avalon Peninsula of Newfoundland, Canada. Subjects for this study were a
cohort of individuals with T1D who participated in a genetics study between 2001
and 2006. At the time of that study, demographic and clinical information from each
individual had been entered in the Newfoundland and Labrador Diabetes Genetics
Database and was used as a basis for patient contact. Later, given the passage of
time, the most up to date demographic information about the cohort was collected.
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According to Newhook et al. [40] paper “the Avalon Peninsula of Newfoundland
has one of the highest incidences of T1D reported worldwide”. The obtained raw
T1D dataset comprises 239 features concerning demographical, clinical and genotype
factors from 196 patients. This dataset is heterogeneous and have missing values
especially in its genotype information. These imperfections drive us to perform the
following pre-processing steps before applying the two selected methods.
Irrelevant features elimination: Not all of 239 features in the raw dataset is re-
lated to our research. We eliminate 25 irrelevant features such as “number of
patient visits to the hospital” or “patient insurance status”.
Sparse raws elimination: In the raw dataset, we have overall 12724 (27.2%) miss-
ing entries. We eliminate 43 patients (rows) which have more than 50% missing
entries to reduce data sparsity.
Complications matrix extraction: 20 features are representing patients compli-
cation data. We extracted these columns and named them as complications
matrix. Complications (columns) with more than 75% missing entries are elim-
inated from the obtained matrix. We consider that minimum sample size to
analyze a complication is at least ten patients; thus complications with less
than eleven patients are excluded. Eventually, we obtained a 153× 10 compli-
cations matrix. Missing values in complications are replaced with zero (healthy
status).
Substituting values and merging categories: Some of the raw dataset entries
are text. For each unique string, a number is assigned and strings were replaced
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by their corresponding number for better computational handling. Additionally,
in each column, low population categories are merged to achieve a larger cate-
gory. Additionally, patients date of birth is converted to age and its calculated
until 2016.
Genotype features: We have 122 genotype features in total which 98 of them are
categorical with three categories (homozygous, heterozygous type 1, heterozy-
gous type 2) in each column. However, the rest (24 columns) are categorical
while each data entry holds the position of an allele in the chromosome. We
rearranged these features into binary features which whether they have an allele
in the given position or not. This results in removing 24 features and adding
330 binary genotype features.
Sparse raws elimination: For the final step, we eliminate 64 features (columns)
which have more than 30% missing entries to reduce data sparsity. This number
is found empirically as a compromise between the number of rows eliminated
and amount of missing data.
Following the mentioned steps we have a 153×436 T1D pre-processed dataset and
a 153× 10 complications data matrix. We use the T1D pre-processed dataset as our
input data. The complications matrix is used for evaluating the obtained clusters to
identify clusters with higher incidence of having complications. Table 1.1 represents a
summary of pre-processed T1D dataset features and Appendix A includes all dataset
features details and their specification.
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Table 1.1: T1D Dataset Features Summary
Features Category Features Type No. of Features
Patient Clinical Data Ordinal, Numeric, Binary 24
Relative Clinical Data Binary 24
Patient Demographic Data Numeric 4
Patient Genotype Data Categorical, Binary 384
1.5 Study Overview
In this chapter, we introduced T1D and provided an overview of our input dataset. In
the second chapter, we describe the basis of GLRM and the methods used to identify
over enriched clusters. Then we present GLRM result and discuss its outcomes. In
the third chapter, we present the principles of SNF, then we present the achieved
result and discuss its features. Finally, in the last chapter, we give a comprehensive
summary of our research. Figure 1.1 illustrates our work-flow and thesis organization.
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Figure 1.1: Research work flow diagram
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Chapter 2
Generalized Low Rank Modeling
2.1 Introduction
Artificial Intelligence (AI) and Machine Learning (ML) methods have been used ex-
tensively for analyzing health records data and patient stratification. Researchers
dealing with these methods are thwarted by imperfect data characteristics such as
missing data records, mixed type of features, heterogeneity, and sparsity. We use Gen-
eralized Low Rank Modeling (GLRM) as a framework for analyzing our pre-processed
Type 1 Diabetes (T1D) dataset described in Section 1.4. Unlike typical machine learn-
ing algorithms, this framework offers flexible solutions to overcome data barriers such
as missing data and heterogeneity. The GLRM framework was first introduced by
Udell et al. [1]. It extends Principle Component Analysis (PCA) technique [41] to
design a framework which can handle heterogeneous data with mixed feature types
(numerical and categorical). This framework transforms high-dimensional data into
lower dimension space by solving an optimization problem.
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Prior to applying the GLRM to the T1D raw dataset, we perform data prepro-
cessing steps discussed in Section 1.4 including merging, replacing and segregating
features values as well as eliminating sparse samples. Following the data preparation
step, we apply the GLRM method to the pre-processed T1D dataset and optimize
its parameters using cross-validation. Consequently, the low dimensional data with
minimum error obtained after cross-validation is used for further analysis. Three
clustering algorithms (K-means [42], Hierarchical [43], and Affinity Propagation [44]
clustering) are applied to the optimal low-dimensional data, and then, the results are
evaluated with various statistical tests.
In this chapter, we describe the principles of GLRM framework and clustering
algorithms in the methods section. Next, we discuss the outcome of each procedure
in the results section and finally, we illustrate how GLRM helped us to achieve a
patient stratification strategy for T1D patients.
14
2.2 Methods
In this section, we describe the procedure that we followed to group T1D patients from
pre-processed dataset. We will discuss each of the following topics in a subsection:
• Summary of the GLRM framework principles, the philosophy behind it and the
software package used for it.
• Description about optimal low-dimensional concise data extraction and how we
find the proper parameter set for building the model.
• Reviewing the basis of three clustering methods, including K-means, hierar-
chical, and affinity propagation clustering, which we use for analyzing low-
dimensional data.
• Finally, investigating clustering results to find the relation between clusters and
complications.
2.2.1 GLRM Framework
Unavoidable imperfections in data such as noise, missing entries, sparsity, and het-
erogeneity have challenged common machine learning methods in previous studies for
finding patterns in clinical health-related data [45]. Udell et al. [1] extended the idea
behind Principal Components Analysis (PCA) into a generalized method that can
handle different types of data sets including numerical, boolean, categorical, ordinal,
and other data types. Generalized Low Rank Modeling (GLRM) handles heteroge-
neous datasets, compresses and denoises data, and imputes missing records. We apply
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this method to deal with a large number of input data features and to utilize most of
the samples even if they have missing values in some features.
GLRM represents high dimensional bulk data in a lower-dimensional space. Sup-
pose we have a matrix A that has m rows representing samples and n columns that
represent n features while these features have different types of data; for instance,
one column may take float values while the others have categorical values. By solving
an optimization problem, we can approximate A by X as a “tall and skinny” matrix
and Y as a “short and wide” matrix (Figure 2.1). X represents k new latent features
for m samples, and Y encodes the transformation of n original features into the k
new latent features.
Figure 2.1: Matrix transformation with GLRM framework (obtained from
Udell et al. [1])













Where Lij(xiyj, Aij) is the loss function, xiyj is the predicted entry which is ob-
tained by matrix production of the ith row of estimated X matrix and the jth column
of estimated Y matrix, Aij is the observed entry in the input data; rx and ry are
regularizers used to limit output matrices. The loss function (first sigma operand)
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measures the accuracy of data approximation, and the problem-solving algorithm will
try to minimize this part. Different loss functions are appropriate for various types of
data inputs. Thus, GLRM gives the flexibility to define different functions for each
column of data (features) based on their type. The loss should be calculated only
over the set Ω which represents non-missing entries. The regularizers rx and ry limits
latent feature values. Choosing appropriate regularization can improve the model and
prevent it from over-fitting. Furthermore, appropriate k value which represents the
number of latent features can be estimated using cross validation over the observed
data and investigating test and train errors.
We use GLRM to estimate and fill out the missing values in our dataset and
transform our big heterogeneous dataset into a smaller homogeneous one. For this
purpose, we use H2O.ai package (version 3.14.0.2)[46] in the R programming lan-
guage [47]. This package has built-in implementations of GLRM framework as well
as popular machine learning algorithms.
Following building an appropriate model for the input dataset, we extract the tall
and skinny matrix X and use it to cluster samples (patients) based on the k latent
features obtained by GLRM.
2.2.2 GLRM Parameter Setting
To make a low-rank model converge efficiently, we need to choose proper input param-
eters. Udell et al. [1] thoroughly described the impact and purpose of each parameter
in GLRM implementation. To achieve an optimal performance, parameters must be
fitted based on the dataset. Here we briefly describe input parameters including loss
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functions (Lj), regularizers(r, r̃) gamma (γ), and output matrix rank (k).
Loss function (Lj): The loss functions is defined for each column (feature) based
on its data nature. According to Udell et al. [1] and GLRM implementation in
H2O [46], we use “quadratic”, “logistic”, “categorical” and “ordinal” loss func-
tions for numerical, boolean, categorical, and sequential features, respectively.
Regularizers(r, r̃) and Gamma (γ) The regularization functions r and r̃ are used
to prevent overfitting or to enforce constraints on the values of low-rank ma-
trices X and Y. These regularizations can be scaled by γ. Thus, the GLRM













Where all the terms are as defined in Equation 2.1, γx and γy are scaling val-
ues for the regularizers. Our input dataset has many missing values, and this
can prevent the model from overfitting itself. Therefore, we use no regular-
izer for building the low rank model. Additionally, by adding the regularizers
to the model, we observed that test and train errors in cross validation were
significantly increased.
Rank (k): Rank of a model is the number of columns in the concise low-rank matrix
(X). We use cross validation over the input data and find a proper rank based
on the train and test error.
In addition to these parameters, we need to set the low-rank matrices initialization
method, Udell et all [1] showed that a suitable approach for matrices initialization is
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“Singular Value Decomposition (SVD)” [48] which performs much better than other
random initialization methods.
Lastly, following the determination of well-fitted parameters for building the model,
we can extract low-rank matrices X and Y . X represents sample features in a dif-
ferent domain while it has homogeneous data with no missing entries. It has m rows
which is equal to the number of samples and k columns which represent k latent
features. Y with the size of k × n, represents the relation between k latent features
and n original features. We call X matrix “concise data” and will use it to cluster
patients.
2.2.3 Data Clustering
Patients grouping helps clinicians to investigate the diseases cause in a group [36]. Our
input dataset, contains patients complications data as well as clinical, demographical
and genetic data. As indicated in Section 1.4 we separate features set into two
categories: 1- complications features, 2- Other features. The second features category
is used as the input data for building the GLRM model, extracting the concise data
and clustering samples based on this concise matrix. The first features category is
used to evaluate the clustering results. In this section, we first describe the algorithms
used for clustering the concise data (each cluster represents a group of patients), and
then we explain how we evaluate clustering results to discover the relationship between
clusters and complications.
K-means Clustering: k-means clustering aims to partition m samples into k clus-
ters while each sample fits the cluster with the nearest mean [42]. We use
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kmeans function in Matlab® Statistics and Machine Learning Toolbox for clus-
tering the concise data [49]. This function needs the number of clusters to be
determined as the input; we empirically set this number to 10. Other cluster-
ing methods which do not require the number of clusters as an input indicated
roughly the same number of clusters as well. Euclidean distance is used for
distance measurement between data points.
Hierarchical Clustering: Hierarchical clustering groups data by forming a cluster
tree or dendrogram [43]. The tree is a multilevel hierarchy where clusters at one
level are joined as clusters at the next level [50]. There are two strategies for
hierarchical clustering: Agglomerative and Divisive. The agglomerative strat-
egy is a “bottom up” approach in which each sample has its own cluster, and
two clusters are merged as one moves up the hierarchy. On the other hand,
the divisive strategy is a “top down” approach which all samples are gathered
in one cluster, and then splits are performed as one moves down the hierar-
chy [51]. We use clusterdata function in Matlab® Statistics and Machine
Learning Toolbox for clustering concise data [49]. This function supports ag-
glomerative clustering. We use Euclidean distance as the distance metric, and
inner squared distance (minimum variance algorithm) as the algorithm for com-
puting distance between clusters, more information about the function inputs
are available at Matlab user guide in hierarchical clustering [50]. Finally, after
applying hierarchical clustering to the concise data, we choose a proper value
for the maximum number of clusters based on the obtained dendrogram. We
select a cutting level on the dendrogram where clusters are neither too small (at
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least three members in each cluster) nor too big (not more than 40 members in
each cluster).
Affinity Propagation Clustering: Affinity propagation clustering is an algorithm
based on the concept of “message passing” between samples, and it does not re-
quire the number of clusters to be determined before running the algorithm [44,
52]. We use apcluster function in Matlab® for clustering our data, more infor-
mation about the algorithm and function parameters are available at Frey et al.
article [44]. This function requires two inputs: 1- A square matrix representing
pairwise similarities between two samples. We use the negative of Euclidean
distance as the pairwise similarity measure. 2- An input preference p which is a
real-valued vector. pi indicates the preference that data point i be chosen as an
exemplar. We set all preferences to a same value since we have no preferences
among the samples.
2.2.4 Clusters Evaluation
As indicated in Section 1.4, we extract patients complications information from raw
input dataset and name this extracted data as the complications matrix. The compli-
cations matrix is a binary data which contains 153 rows corresponding to the number
of patients and ten columns corresponding to the number of accessible complications
information.
The results of each clustering algorithm is a vector indicating the cluster assign-
ment for each patient. For each clustering result, we apply three statistical measures
per complication to investigate if there is any relation between a group of patients
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and a disease. These measures are hypergeometric test, odds ratio, and risk ratio.
Hypergeometric Test: The hypergeometric test is based on the hypergeometric
distribution to calculate the significance of having drawn a specified number
of successes from a specified population. This test can be used to distinguish
which subsets of the population are over- or under-represented in a clustering
scheme [53].
We use Matlab® hygecdf function to “compute the complement hypergeomet-
ric cdf at the value of x using the corresponding size of the population (M),
total number of items with the desired characteristic in the population (K), and
number of samples drawn (N). The result, p, is the complement probability of
drawing up to x of a possible K items in N drawings without replacement from
















We define x as the number of patients with specified complication in the cluster,
M as the total number of patients (population size), K as the total number of
patients with specified complication, and N as the cluster size. The obtained
p value represents the probability in the null distribution of observing up to x
patients with the specified complication in the given cluster. Thus, the lower
probability means a more reliable cluster that could adequately capture patients
with a specified disease. However, this probability is very low in the small
clusters (such as clusters with less than four patients), which is not desired;
therefore we add other methods to evaluate clustering results.
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Risk Ratio: Risk ratio or relative risk (RR) is the probability of an event occurring
in an exposed group divided by the probability of the event occurring in a
comparison, non-exposed group [54].
Table 2.1: Exposed and diseased population ratio definition
Diseased Healthy Total
Exposed DE HE NE = DE +HE
Not exposed DN HN NN = DN +HN





A RR = 1 represents no difference in risk between the exposed and non-
exposed group. However, RR < 1 means the event is less likely to occur in the
exposed group than in the not exposed group, and a RR > 1 means the event
is more likely to occur in the exposed group. We count “Diseased” population
as the patients with a specific complication and “Exposed” population as the
patients inside a cluster. Consequently, clusters with higher risk ratio are more
reliable clusters which they could represent patients more likely to develop a
given complication.
Odds Ratio: The odds ratio (OR) is used commonly to quantify how strongly the
presence or absence of an exposure is associated with an outcome in a given
population. If OR = 1 it means that the exposure does not affect odds of the
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outcome. OR > 1 indicating that the exposure is associated with higher odds
of outcome and OR < 1 is the opposite case [55, 56].





When the OR is one, the RR will be equal to one as well and OR approximates
RR if the probability of the disease occurrence is low. However, the OR is always
bigger compared to RR; thus, OR can better represent slight differences. We
use OR for plotting our results, but it should be kept in mind that a small
cluster (such as clusters with less than four patients) may have very high OR.
To find the significant level of odds ratio in each cluster given a complication, we
bootstrap obtained clustering result for each clustering method and determine the
p-value for the odds ratio per cluster given a complication. For this purpose, 10000
random set of cluster labels are produced while the total number of clusters and
cluster’s size are identical to the original clustering result. Then, for each complication
given a cluster, the p-value is measured by dividing the number of results from the
random sampling with an OR greater or equal to the real OR, divided by total number
of results from the random sampling.
By evaluating the clustering results from k-means, hierarchical and affinity prop-
agation clustering algorithms using the three outlined measurements, we can find out
whether risk factors for developing a secondary disease related to T1D can be identi-
fied by integrating demographic, clinical and genetic data using the GLRM method.
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2.3 Results
As described in Section 1.4 our pre-processed T1D dataset is segmented into two sep-
arate datasets. First one has 153 samples and 436 features; we call this dataset as the
“T1D pre-processed input data” since we use it for machine learning algorithms
input. The second part of the dataset is a binary matrix with 153 samples and ten
columns representing the presence of ten complications in each patient. This matrix
is used for evaluating the clustering results. We call this matrix the “complications
data”. The input data has 14.75% missing entries, however, the GLRM algorithm
can tolerate this amount of missing data. Table 1.1 represents a summary of input
data characteristics and a detailed table is available in Appendix A.
In this section, we present the cross-validation results to set the GLRM optimal
parameters. Next, we illustrate the results of the clustering algorithms and, finally,
we discuss whether or not discovered clusters are over-enriched with patients having
a given complication.
2.3.1 GLRM Parameter Selection
In section 2.2.2 we discussed methods for finding proper GLRM parameters includ-
ing loss functions, regularizers, and rank. Appendix A includes list of all features
and their types, we use “quadratic”, “logistic”, “categorical” and “ordinal” loss func-
tions for numerical, boolean, categorical and sequential features, respectively. We use
no regularizer for building the low rank model since by adding the regularizers to
the model, we observed that cross validation test and train errors were significantly
increased.
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Cross validation is used for finding a proper rank (k). We use ω portion of observed
samples which is randomly selected as the validation set and the remaining observa-
tions (1− ω) as the training set. Additionally, cross validation is repeated five times
with distinct sets of ω for each set of parameters in GLRM model. Since our input
data is heterogeneous, we use two types of error for evaluating model performance.
Mean Square Error (MSE) used for calculating model errors in numerical features
(only 11 features) and Misclassification Ratio (MCR) used for the rest. Considering
the few number of numerical features, MSE is not a reliable measure for selecting the
parameters, and we decide based on MCR.

















MSE Error as a fucntion of K
Train MSE,  = 0.1
Test MSE,  = 0.1
Train MSE,  = 0.2
Test MSE,  = 0.2
Train MSE,  = 0.5
Test MSE,  = 0.5
Figure 2.2: GLRM model average Mean Square Errors (MSE) on five fold cross
validation results. The horizontal solid lines indicate the MSE on the training data
and the horizontal dotted lines indicate the MSE on the test data. The vertical lines
indicate the standard error.
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Figure 2.2 illustrates the average of MSE, over five cross validations, on train and
test set, for three different ω. Figure 2.3 illustrates MCR with same properties as the
previous figure. As we can observe in the Figure 2.3, train and test errors are both in
their minimum values after k = 70. Thus, we choose k = 70 as the proper rank and
extract the X matrix which has 153 samples and 70 latent features. As it mentioned,
we call this matrix “concise data”.



















MCR Error as a fucntion of K
Train MCR,  = 0.1
Test MCR,  = 0.1
Train MCR,  = 0.2
Test MCR,  = 0.2
Train MCR,  = 0.5
Test MCR,  = 0.5
Figure 2.3: GLRM model average Misclassification Ratio (MCR) on five fold cross
validation results. The horizontal solid lines indicate the MCR on the training data
and the horizontal dotted lines indicate the MCR on the test data. The vertical lines
indicate the standard error.
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2.3.2 Clustering Concise Data
Three algorithms described in Section 2.2.3 are used to cluster the concise data. In this
section, we first represent and analyze each clustering results, then, we address clusters
over-enriched with patients having T1D secondary diseases. Table 2.2 illustrates an
overview of three clustering methods’ results.
Table 2.2: Overview of GLRM three clustering methods’ results
k-means Hierarchical Affinity Propagation
No. of clusters 10 9 11
Clusters’ Size Average ± SD 15.3±18.2 17±11.5 13.9±10.3
Median Clusters’ Size 9.5 15 17
Maximum Clusters’ Size 63 38 36
Minimum Clusters’ Size 3 3 1
2.3.2.1 K-means Clustering
As it explained in Section 2.2.3, we use kmeans function in Matlab® for clustering the
concise data. Number of desired clusters (k) is empirically set to ten; other clustering
methods which do not require to specify the number of clusters a priori indicated
roughly the same amount for the number of clusters as well. Table 2.3 illustrates
demographic statistics regarding k-means output clusters.
We evaluate clustering outcome using three statistical measures including Hyper-
geometric test, odds ratio, and risk ratio which are described in Section 2.2.4.
Figure 2.4 represents odds ratio for each complication and cluster. Numbers in
each cell represents total number of patients with the specified complication in the
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Table 2.3: Statistics of the patients clusters obtained using k-means clustering
Cluster Size Male(%) Female(%) Weight (kg) Age
Cluster #1 14 7.1 92.9 81.0 ± 18.1 33.1 ± 7.2
Cluster #2 3 100.0 0.0 91.7 ± 20.6 25.7 ± 2.9
Cluster #3 11 54.5 45.5 80.1 ± 14.9 30.7 ± 6.0
Cluster #4 12 0.0 100.0 62.8 ± 7.2 27.1 ± 4.9
Cluster #5 7 14.3 85.7 68.7 ± 12.2 51.6 ± 10.7
Cluster #6 27 51.9 48.1 82.5 ± 16.0 47.9 ± 11.0
Cluster #7 4 50.0 50.0 111.1 ± 35.0 31.5 ± 7.6
Cluster #8 8 75.0 25.0 92.2 ± 15.7 37.6 ± 15.1
Cluster #9 63 46.0 54.0 77.5 ± 15.3 29.5 ± 6.4
Cluster #10 4 50.0 50.0 76.3 ± 15.1 29.8 ± 8.4
Weight and age columns values indicate corresponding average ± standard deviation.
specified cluster.
Figure 2.5 illustrates the three clusters with the highest odds ratio for each com-
plication while clusters with less than four members are filtered out. Each bubble
represents the odds ratio for a cluster concerning the specified complication, and
bubbles sizes are proportional to the number of patients with a given complication.
Table 2.4 shows statistical measures for the cluster with highest odds ratio con-
cerning each complication while clusters with less than four members are filtered out.
Entire clustering evaluation measures are available in Section B.1 in Appendix B.

















































































































































































































Thyroid Disease (Total = 25)
Dyslipidemia (Total = 27)
High Blood Pressure (Total = 29)
Nerve Damage (Total = 15)
Retinopathy (Total = 37)
Diabetic Ketoacidosis (Total = 34)
Hyperglycemia (Total = 37)
Hypoglycemia X (Total = 24)
Anxiety (Total = 19)



















Figure 2.4: Heatmap for k-means clustering indicating the calculated odds ratio per complication for obtained clusters
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Cluster 1 (Size = 14)
Cluster 2 (Size = 3)
Cluster 3 (Size = 11)
Cluster 4 (Size = 12)
Cluster 5 (Size = 7)
Cluster 6 (Size = 27)
Cluster 7 (Size = 4)
Cluster 8 (Size = 8)
Cluster 9 (Size = 63)
Cluster 10 (Size = 4)
Figure 2.5: Bubble graph for k-means clustering result
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Table 2.4: Most significant results per complication obtained using k-means clustering
OR p-value Cluster # #PCC #CLS #CMP
Diabetic Ketoacidosis 5.91 0.006 4 7 12 34
Hyperglycemia 3.55 0.041 4 6 12 37
Retinopathy 3.39 0.097 8 4 8 37
Hypoglycemia X 3.02 0.095 4 4 12 24
Dyslipidemia 2.96 0.107 3 4 11 27
High Blood Pressure 2.65 0.036 6 9 27 29
Nerve Damage 1.82 0.260 6 4 27 15
Thyroid Disease 1.39 0.294 9 12 63 25
Depression 1.39 0.389 6 4 27 18
Anxiety 1.29 0.437 6 4 27 19
#PCC means number of patients with specified complication in the cluster. #CLS
represents total number of patients in the cluster and #CMP shows total number of
patients with specified complication.
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2.3.2.2 Hierarchical Clustering
Agglomerative hierarchical clustering is the second method used for clustering the
concise data. Figure 2.6 illustrates dendrogram of the hierarchical clustering. Each
leaf in the tree corresponds to one data sample. The number of clusters is obtained
by partitioning the dendrogram in a level in which cluster are neither too small (less
than three members) nor too large (more than 40 members). The red line in the










Figure 2.6: Hierarchical Clustering Dendrogram Leaf nodes at the bottom of the
dendrogram present patients. The height of each U represents the distance between
the two connected patient clusters.
Table 2.5 illustrates demographic statistics regarding hierarchical clustering ex-
tracted clusters.
Based on the hierarchical clustering result, we illustrate the algorithms outcome
33
Table 2.5: Statistics of the patients clusters obtained using hierarchical clustering
Cluster Size Male(%) Female(%) Weight (kg) Age
Cluster #1 13 30.8 69.2 88.8 ± 13.9 32.2 ± 7.1
Cluster #2 38 39.5 60.5 73.5 ± 12.9 29.0 ± 4.6
Cluster #3 15 66.7 33.3 78.2 ± 10.8 35.6 ± 9.6
Cluster #4 22 45.5 54.5 78.4 ± 11.9 54.3 ± 7.3
Cluster #5 31 16.1 83.9 68.2 ± 10.5 28.7 ± 5.8
Cluster #6 5 40.0 60.0 80.5 ± 16.1 34.4 ± 7.3
Cluster #7 3 33.3 66.7 62.0 ± 4.7 29.7 ± 6.7
Cluster #8 15 60.0 40.0 111.2 ± 18.5 35.6 ± 13.6
Cluster #9 11 72.7 27.3 82.8 ± 13.3 29.0 ± 5.6
Weight and age columns values indicate corresponding average ± standard deviation.
using a heatmap (Figure 2.7), a bubble plot (Figure 2.8) and a table (Table 2.6)
with same characteristics of the corresponding elements in Section 2.3.2.1. Entire
clustering evaluation measures are available in Section B.1 in Appendix B. Table






























































































































































































Thyroid Disease (Total = 25)
Dyslipidemia (Total = 27)
High Blood Pressure (Total = 29)
Nerve Damage (Total = 15)
Retinopathy (Total = 37)
Diabetic Ketoacidosis (Total = 34)
Hyperglycemia (Total = 37)
Hypoglycemia X (Total = 24)
Anxiety (Total = 19)



















Figure 2.7: Heatmap for hierarchical clustering indicating the calculated odds ratio per complication for obtained clusters
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Cluster 1 (Size = 13)
Cluster 2 (Size = 38)
Cluster 3 (Size = 15)
Cluster 4 (Size = 22)
Cluster 5 (Size = 31)
Cluster 6 (Size = 5)
Cluster 7 (Size = 3)
Cluster 8 (Size = 15)
Cluster 9 (Size = 11)
Figure 2.8: Bubble graph for hierarchical clustering result
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Table 2.6: Most significant results per complication obtained using hierarchical clus-
tering
OR p-value Cluster # #PCC #CLS #CMP
Nerve Damage 6.40 0.007 3 5 15 15
High Blood Pressure 3.33 0.041 3 6 15 29
Hypoglycemia X 2.30 0.075 5 8 31 24
Thyroid Disease 2.21 0.124 4 6 22 25
Dyslipidemia 2.06 0.090 2 10 38 27
Retinopathy 1.66 0.160 2 12 38 37
Hyperglycemia 1.66 0.280 3 5 15 37
Diabetic Ketoacidosis 1.63 0.323 1 4 13 34
Depression 0.85 0.706 2 4 38 18
Anxiety 0.78 0.751 2 4 38 19
#PCC means number of patients with specified complication in the cluster. #CLS
represents total number of patients in the cluster and #CMP shows total number of
patients with specified complication.
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2.3.2.3 Affinity Propagation Clustering
Affinity Propagation clustering is the third methods used for clustering the concise
data. This method does not need the number of clusters to be determined. Table 2.7
illustrates demographic statistics regarding affinity propagation clustering extracted
clusters.
Table 2.7: Statistics of the patients clusters obtained using affinity propagation clus-
tering
Cluster Size Male(%) Female(%) Weight (kg) Age
Cluster #1 3 33.3 66.7 106.7 ± 27.6 57.7 ± 5.1
Cluster #2 1 0.0 100.0 159.1 ± 0.0 42.0 ± 0.0
Cluster #3 12 33.3 66.7 72.7 ± 15.7 30.1 ± 5.5
Cluster #4 17 52.9 47.1 75.2 ± 10.5 31.4 ± 13.7
Cluster #5 17 23.5 76.5 67.1 ± 12.8 30.2 ± 9.3
Cluster #6 20 50.0 50.0 77.0 ± 15.4 29.7 ± 8.4
Cluster #7 36 50.0 50.0 81.8 ± 15.3 42.0 ± 11.2
Cluster #8 19 15.8 84.2 85.0 ± 19.9 34.5 ± 10.8
Cluster #9 1 0.0 100.0 56.8 ± 0.0 34.0 ± 0.0
Cluster #10 18 66.7 33.3 85.6 ± 12.8 31.2 ± 9.2
Cluster #11 9 33.3 66.7 72.8 ± 10.3 31.1 ± 4.6
Weight and age columns values indicate corresponding average ± standard deviation.
We illustrate the algorithms outcome using a heatmap (Figure 2.9), a bubble plot
(Figure 2.10) and a table (Table 2.8) with same characteristics of the corresponding
elements in Section 2.3.2.1. Entire clustering evaluation measures are available in









































































































































































































































Thyroid Disease (Total = 25)
Dyslipidemia (Total = 27)
High Blood Pressure (Total = 29)
Nerve Damage (Total = 15)
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Diabetic Ketoacidosis (Total = 34)
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Figure 2.9: Heatmap for affinity propagation clustering indicating the calculated odds ratio per complication for obtained
clusters
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Cluster 1 (Size = 3)
Cluster 2 (Size = 1)
Cluster 3 (Size = 12)
Cluster 4 (Size = 17)
Cluster 5 (Size = 17)
Cluster 6 (Size = 20)
Cluster 7 (Size = 36)
Cluster 8 (Size = 19)
Cluster 9 (Size = 1)
Cluster 10 (Size = 18)
Cluster 11 (Size = 9)
Figure 2.10: Bubble graph for affinity propagation clustering result
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Table 2.8: Most significant results per complication obtained using affinity propaga-
tion clustering
OR p-value Cluster # #PCC #CLS #CMP
Dyslipidemia 4.21 0.052 11 4 9 27
Diabetic Ketoacidosis 3.04 0.111 11 4 9 34
Nerve Damage 2.40 0.099 7 6 36 15
Hyperglycemia 2.23 0.108 10 7 18 37
Anxiety 2.12 0.199 8 4 19 19
Thyroid Disease 2.10 0.090 7 9 36 25
Hypoglycemia X 1.78 0.254 4 4 17 24
High Blood Pressure 1.78 0.233 10 5 18 29
Retinopathy 1.53 0.291 8 6 19 37
Depression 0.92 0.657 7 4 36 18
#PCC means number of patients with specified complication in the cluster. #CLS
represents total number of patients in the cluster and #CMP shows total number of
patients with specified complication.
2.4 Discussion
We have an input dataset from T1D patients with no control data (no healthy sam-
ples), we compressed this dataset using GLRM and applied three clustering algo-
rithms to identify groups of patients at higher risk of developing T1D complications.
We found that, k-means clustering result is not stable; it produces a different cluster-
ing result on each run since the initialization is random and the algorithm is not able
to converge. Therefore, it seems that k-means is not a proper clustering algorithm
for our data and we avoid further analysis on the k-means clustering result.
Based on the hierarchical clustering result, by considering the odds ratio value
for each cluster given a compilation and its corresponding p-value (Table B.42), we
can state that Cluster #3 with 15 members is enriched with patients who suffer from
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nerve damage and high blood pressure. These two complications have the odds ratio
of 6.4 (with p-value = 00.7) and 3.3 (with p-value = 0.041), respectively in Cluster
#3.
On the other hand, according to affinity propagation clustering result, by consid-
ering the odds ratio value for each cluster given a compilation and its corresponding
p-value (Table B.43), Cluster #11 with 9 members, is enriched with Dyslipidemia pa-
tients and this complication’s odds ratio is 4.2 (with p-value = 0.052) in this cluster.
Table 2.9: Concordance between affinity propagation clustering and hierarchical clus-










Cluster #1 1.1 2.4 1.2 1.5 2.0 0.6 0.4 27.0 0.9
Cluster #2 0.5 1.3 0.6 0.8 1.1 0.3 0.2 13.7 0.5
Cluster #3 0.0 12.3 2.8 3.8 0.1 1.4 1.0 2.8 2.3
Cluster #4 1.7 0.4 0.1 0.1 0.7 1.7 1.9 3.6 2.6
Cluster #5 0.2 0.4 3.6 1.2 11.0 0.5 1.9 3.6 2.9
Cluster #6 0.4 0.2 0.0 0.3 0.0 0.3 1.4 0.6 0.2
Cluster #7 0.0 4.8 5.5 10.7 0.8 0.0 2.3 0.8 1.4
Cluster #8 0.1 0.1 0.0 0.2 0.0 0.3 1.4 0.7 0.1
Cluster #9 0.5 1.3 0.6 0.8 1.1 0.3 43.6 0.6 0.5
Cluster #10 0.3 2.7 0.5 1.3 0.1 0.4 1.3 0.9 3.1
Cluster #11 0.1 0.0 2.3 3.1 0.6 1.1 0.8 2.3 22.9
Rows and columns indicate affinity propagation clustering and hierarchical clustering,
respectively. A higher NMI percentage implies greater concordance between clusters.
Table 2.9 shows the concordance between the affinity propagation and the hierar-
chical clustering results based on NMI percentage. We use percentage of Normalized
Mutual Information (NMI) [57, 58] for measuring the concordance of two clustering
result. NMI is a value between 0 and 1 and NMI percentage is between 0 to 100. NMI
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can be calculated using NMI = I(U,V )√
H(U)H(V )
, where U and V are two sets of clustering
results from the same input data. I(U, V ) is the mutual information between U and
V ; and H is the entropy of the given clustering result; calculation details are available
at Vinh et al. [57]. As we can observe in Table 2.9, the two clustering methods does
not have any significant concordance, this is supported by the fact that the obtained
result from the two methods are completely different.
As a future work, one would need to investigate what factors cause patients to
develop T1D related complications such as nerve damage and Dyslipidemia, since we
found clusters enriched with these complications.
2.5 Conclusion
Machine Learning algorithms have been used broadly for analyzing data, however, re-
searchers dealing with those methods are challenged by imperfect data characteristics
such as missing data and heterogeneity. We used Generalized Low Rank Modeling
(GLRM) for analyzing our input dataset to discover patients subgroups more likely
to have a given complication. This framework can overcome data barriers like missing
data and heterogeneity. In a nutshell, we took following steps to identify groups of
patients at higher risk of developing T1D complications using demographic, clinical
and genetic data.
1. Cleansed raw dataset (we call the clean data as the “input data”)
2. Applied GLRM framework with a proper parameter set to the input data.
3. Extracted the “concise data” from GLRM output.
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4. Applied three clustering algorithm: k-means, hierarchical and affinity propaga-
tion clustering to the concise data.
5. Evaluated the clustering with patients complications information and found
clusters that are over-enriched with patients having secondary diseases related
to T1D.
According to the achieved result, we identified clusters enriched with patients
having nerve damage, high blood pressure and Dyslipidemia. Consequently, we have
taken first steps to identify groups of patients at higher risk of developing T1D com-
plications. This results could be taken as the basis to develop a predictive model that
could allow patients and health-care providers to take preemptive steps to reduce the





Current technology delivers the opportunity to efficiently collect diverse clinical, de-
mographic and genetic data to address biological questions. However, powerful com-
putational methods are needed to investigate these data and create a comprehensive
view of a biological progresses such as developing a diseases. Systems biology ap-
proaches and more specifically, network-based techniques have emerged as powerful
tools for studying complex diseases. We use Similarity Network Fusion (SNF) [2] to
reveal the links among clinical, demographic and genetic data to facilitate patients
stratification and to distinguish those patients at a higher risk of developing T1D
complications.
SNF uses networks of samples as a basis for integration. The fused output net-
work captures both shared and complementary information from all input datasets
and offers the main view about how informative is each dataset by comparing the ob-
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served similarity between samples. SNF can present valuable information from even
a small number of samples. This algorithm is robust to noise and can be used with
heterogeneous data. The fused network is used to classify subtypes among patients
using network clustering.
Prior to applying the SNF to the raw dataset, we perform data preprocessing
steps discussed in Section 1.4 including merging, replacing and segregating features
values as well as reducing sparse samples. Following the data preparation step, we
implement data imputation to eliminate missing values. Based on the features types,
six sub-datasets are derived and each one is used to generate a patients similarity
network. We apply the SNF method to merge all patients networks together and
produce a single network. Finally, spectral clustering is applied to the fused network
and then the result is evaluated with various statistical tests.
In this chapter, we describe the data imputation and sub-dataset extracting step,
then we present the principles of the SNF and network clustering. Next, we see the
outcome of each procedure in the results section and finally, we discuss how SNF
helps us to stratify T1D patients.
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3.2 Methods
Section 1.4 explains how we cleansed the original raw data and segmented it into two
datasets. One entitled as “pre-processed data” which contains 436 features from 153
patients and the other entitled as “complications data” which presents ten compli-
cations information for each patient. Here, we cluster the input data by applying
Similarity Network Fusion (SNF). Following topics are discussed in this section:
1. Data pre-processing for Similarity Network Fusion
2. Principles of Similarity Network Fusion
3. Network Clustering
Following the clustering step, we evaluate the results using methods outlined in Sec-
tion 2.2.4 to investigate if there is any relation between a cluster patients and a
disease.
3.2.1 Data Pre-Processing
SNF requires each data type as an individual similarity network. Thus, we segment
the input data features into six categories while each category comprises identical
data types - i.e., we partition the input data into six matrices while each one holds all
samples from chosen features set. Appendix A illustrates all data features and their
types and Table 3.1 presents a summary of six derived features’ categories and their
attributes. We name each category’s data a “classified data”.
SNF does not tolerate missing data. Thus, we impute missing entries in the input
data using two approaches based on the features’ types: 1- Mode of each column is
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Table 3.1: Summary of six derived features’ categories
No. Features Data Type Description
Category #1 5 Ordinal Overall health status data
Category #2 7 Numeric Clinical data
Category #3 12 Binary Clinical data
Category #4 4 Numeric Demographic data
Category #5 24 Binary Relatives clinical data
Category #6 384 Categorical Genetic variables data
used to fill missing values in ordinal, categorical and binary features. 2- Observed
entries average in a column is used to fill missing values in the numerical features.
Additionally, ordinal and numerical features are normalized using Equation 3.1






Where f implies any feature and f̃ is the corresponding feature after normalization.
E(f) and V ar(f) represent mean and variance of f , respectively [2].
3.2.2 Principles of SNF
Similarity network fusion (SNF) uses networks of samples as a basis for data inte-
gration. Although networks of samples have been used in other contexts previously,
Wang et al. [2] intended patients-similarity networks for biological data integration.
SNF algorithm can be wrapped-up into two steps: 1- Construction of patients’ simi-
larity network for each data type, 2- Fusing these networks toward a single similarity
network by applying a nonlinear integration method. The driven fused network com-
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prises both shared and complementary data among all feed sources.
Figure 3.1 illustrates a schematic example of SNF steps. Two types of data in-
cluding mRNA expression and DNA methylation from the same cohort of patients
are used to demonstrate this schematic. In this figure, we can observe: “(a) Ex-
ample representation of mRNA expression and DNA methylation data sets for the
same cohort of patients. (b) Patient-by-patient similarity matrices for each data type.
(c) Patient-by-patient similarity networks, equivalent to the patient-by-patient data.
Patients are represented by nodes and patients’ pairwise similarities are represented
by edges. (d) Network fusion by SNF iteratively updates each of the networks with
information from the other networks, making them more similar with each step. (e)
The iterative network fusion results in convergence to the final fused network. Edge
color indicates which data type has contributed to the given similarity.” This figure
and its descrption obtained from Wang et al. [2].
We use Matlab® SNF software package developed by Wang et al. [2] for applying
SNF algorithm to our T1D input data.
Figure 3.1: Schematic representation of SNF steps (obtained from Wang et al. [2])
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The first step in SNF is to create a network for each data type. Suppose we
have n samples and m features from each input data types. A patient similarity
network is represented as a graph G = (V,E) where vertices V present the patients
x1, x2, ..., xn and edges E represent the similarity weight between patients. Edge
weights are described by an n × n matrix W where W (i, j) indicates the similarity
between two corresponding patients. W (i, j) is determined based on patients pairwise
distance using affinityMatrix function in Matlab® SNF package. This function
requires three inputs: a square matrix P representing patients pairwise distance, K
as the number of neighbourhoods and, µ as a hyper parameter in the SNF method.
A comprehensive explanation of these parameters and this function is available at
Wang et al. paper [2].
As Wang et al. [2] proposed, SNF method is not sensitive to these two free parame-
ters (µ and K). The suggested range for µ is between 0.3 to 0.8 and the rule of thumb
for choosing parameter K is K = N/C, where N is the number of patients, and C
is the number of clusters that is assumed to be in the input data. We take µ = 0.8
and K = 15 since we have 153 patients and roughly ten clusters. We will describe a
method for choosing an accurate number of the clusters in the next section. Matrix P
is obtained using Matlab® pdist function which requires data samples and distance
measurement type as inputs. We choose Squared Euclidean distance for ordinal and
numerical data types and Hamming distance for categorical and binary data types.
By following the stated steps for each sub-dataset, we obtain six edge weights ma-
tricesW , each one representing a similarity network. We use SNF function in Matlab®
SNF package to fuse all networks into a single network. This function requires three
inputs: an array of obtained W matrices, K as the number of neighbourhoods and
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T as the number of iterations. K is already decided earlier, and T is set to 25 as it
suggested by Wang et al. paper [2]. The output is an n× n matrix which illustrates
the fused network. Complete information about methods used to achieve the fused
network is available at Wang et al. paper [2]
Using the Concordance Network NMI function in Matlab® SNF package, we deter-
mine the concordance among input networks and fused network based on normalized
mutual information (NMI) which is described in Section 2.4.
3.2.3 Network Clustering
We obtained n × n matrix representing the fused network, and now we want to
identify C clusters out of it. According to the Wang et al. paper [2] we use spectral
clustering [59] which is beneficial for capturing the global structure of the given graph.
This method aims to minimize RatioCut [60] by solving an optimization problem. It
provides two main approaches to decide the best number of clusters: 1- Analyzing the
Eigengap based on the connectivity of the network [59] 2- Analyzing the Eigenvectors
of the Laplacian L [61]. We use SpectralClustering in Matlab® SNF package to
cluster the fused network. This function requires the fused network and number of
clusters C as inputs while C is determined based on the two mentioned methods.
Following the network clustering step, we have a vector which represents a cluster
label for each patient. We evaluate this result by applying three statistical measures
per complication to investigate if there is any relation between a cluster patients and
a disease. These measures include hypergeometric test, odds ratio, and risk ratio.
Detailed description of these methods are available in Section 2.2.4.
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3.3 Results
The T1D input data is imputed and normalized using the methods outlined in Section
3.2.1. We segment the input data features into six categories while each category
comprises identical data types. Following that, a similarity network is constructed
for each sub-dataset. Obtained networks are merged by applying SNF, and finally,
the fused network is clustered using network clustering. Table 3.2 represents networks
concordance based on NMI percentage.








Fused Network 100.0 - - - - - -
Network #1 49.3 100.0 - - - - -
Network #2 17.9 13.5 100.0 - - - -
Network #3 18.9 15.2 13.2 100.0 - - -
Network #4 24.9 12.5 16.0 24.2 100.0 - -
Network #5 33.3 11.2 13.4 13.2 13.8 100.0 -
Network #6 17.6 12.9 10.6 13.1 16.6 15.9 100.0
In this section, we present the obtained clustering result; later we evaluate the




Network clustering (described in Section 3.2.3) is used to cluster the fused network.
This method requires the number of clusters to be determined as an input. Two
estimation methods including eigengap and rotation cost (eigenvectors of the Lapla-
cian) suggest two and nine as the number of believed clusters, respectively. We accept
nine because the other clustering approaches discovered a number of clusters closer to
nine. Table 3.3 illustrates an overview of the clustering result and Table 3.4 illustrates
statistics of the extracted clusters.
Table 3.3: Overview of SNF network clustering result
Network Clustering
No. of clusters 9
Clusters’ Size Average ± SD 17±9.7
Median Clusters’ Size 15
Maximum Clusters’ Size 37
Minimum Clusters’ Size 6
Table 3.4: Statistics of the patients clusters obtained using network clustering
Cluster Size Male(%) Female(%) Weight (kg) Age
Cluster #1 29 69.0 31.0 89.5 ± 20.8 40.0 ± 13.5
Cluster #2 16 25.0 75.0 70.3 ± 15.9 34.9 ± 5.5
Cluster #3 12 16.7 83.3 71.7 ± 10.9 53.5 ± 8.9
Cluster #4 15 46.7 53.3 84.7 ± 19.6 32.3 ± 5.5
Cluster #5 12 16.7 83.3 72.3 ± 8.9 30.5 ± 8.8
Cluster #6 37 32.4 67.6 80.5 ± 14.7 30.4 ± 7.5
Cluster #7 6 83.3 16.7 91.9 ± 18.0 30.7 ± 1.6
Cluster #8 15 53.3 46.7 70.9 ± 10.8 26.9 ± 8.9
Cluster #9 11 36.4 63.6 74.0 ± 19.2 30.5 ± 11.5
Weight and age columns values indicate corresponding average ± standard deviation.
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3.3.2 Clusters Evaluation
We evaluate network clustering outcome using three statistical measures including
Hypergeometric test, odds ratio, and risk ratio which are described in Section 2.2.4.
Figure 3.2 represents odds ratio per complication for each cluster. Value in each
cell represents number of patients with the specified complication in the given clus-
ter. Figure 3.3 illustrates the three most significant clusters (with the highest odds
ratio) for each complication. Clusters with less than four members are filtered out.
Each bubble represents the odds ratio for a cluster concerning the specified compli-
































































































































































































Thyroid Disease (Total = 25)
Dyslipidemia (Total = 27)
High Blood Pressure (Total = 29)
Nerve Damage (Total = 15)
Retinopathy (Total = 37)
Diabetic Ketoacidosis (Total = 34)
Hyperglycemia (Total = 37)
Hypoglycemia X (Total = 24)
Anxiety (Total = 19)



















Figure 3.2: Heatmap for network clustering indicating the calculated odds ratio per complication for obtained clusters
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Cluster 1 (Size = 29)
Cluster 2 (Size = 16)
Cluster 3 (Size = 12)
Cluster 4 (Size = 15)
Cluster 5 (Size = 12)
Cluster 6 (Size = 37)
Cluster 7 (Size = 6)
Cluster 8 (Size = 15)
Cluster 9 (Size = 11)
Figure 3.3: Bubble graph for network clustering result
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Table 3.5 shows statistical measures for the cluster with highest odds ratio con-
cerning each complication while clusters with less than four members are filtered out.
Entire clustering evaluation measures are available Section B.1 in Appendix B. Table
B.44 shows odds ratio p-value for each cluster given a complication.
Table 3.5: Most significant results per complication obtained using network clustering
OR p-value Cluster # #PCC #CLS #CMP
Dyslipidemia 7.16 0.001 4 8 15 27
Thyroid Disease 6.42 0.004 5 6 12 25
Retinopathy 4.30 0.023 9 6 11 37
Anxiety 3.99 0.031 2 5 16 19
Hypoglycemia X 3.27 0.016 1 9 29 24
Depression 3.22 0.080 4 4 15 18
Diabetic Ketoacidosis 2.76 0.094 5 5 12 34
Nerve Damage 2.38 0.122 1 5 29 15
High Blood Pressure 2.38 0.127 4 5 15 29
Hyperglycemia 1.89 0.257 9 4 11 37
#PCC means number of patients with specified complication in the cluster. #CLS
represents total number of patients in the cluster and #CMP shows total number of
patients with specified complication.
3.4 Discussion
We have an input dataset from T1D patients with no control data (no healthy sam-
ples). We segment this dataset into six categories and construct a similarity network
for each data category. These networks are fused into a single network using SNF.
Following that, network clustering is applied to identify groups of patients at higher
risk of developing T1D complications.
By investigating Table 3.2, we can observe that Network #1 has the highest
57
concordance (49.3%) with the final fused network. This indicates that the fused
network is significantly influenced by Network #1 which contains ordinal values from
the features that represents patients overall health status (features list is available at
Appendix A).
Based on the achieved network clustering result, Cluster #1, Cluster #2, Cluster
#4, Cluster #5 and Cluster #9 are promising candidates for further research. Cluster
#1 is enriched with Hypoglycemia patients with the odds ratio of 3.3 (with p-value
= 0.016). This cluster holds 29 patients where eight patients are suffering from both
Hypoglycemia and Hyperglycemia. Cluster #2 enriched with Anxiety patients with
an odds ratio of 4 (with p-value = 0.031). Cluster #4 is enriched with Dyslipidemia
patients with an odds ratio of 7.2 (with p-value = 0.001) and Cluster #5 is enriched
with patients suffering from thyroid diseases with and an odds ratio of 6.4 (with p-
value = 0.004). Cluster #9 is enriched with Retinopathy patients with an odds ratio
of 4.3 (with p-value = 0.023).
As described in the second chapter, we have two significant clustering results from
GLRM method (described in Section 2.3), Table 3.6 shows concordance between hier-
archical clustering (GLRM) and network clustering (SNF) based on Normalized Mu-
tual Information (NMI) percentage (described in Section 2.4). Similarly, Table 3.7
shows the concordance between affinity propagation clustering (GLRM) and network
clustering (SNF). As we can observe in the mentioned tables, there is no significant
concordance between network clustering and the other two methods. This low con-
cordance may indicate that each method is interpreting data uniquely, by detecting
distinct signals from the data. This is supported by the fact that distinct diseases are
over-enriched in the clusters found by each approach.
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Cluster #1 1.2 0.3 2.6 3.0 0.0 2.7 4.7 0.1 2.4
Cluster #2 4.7 0.0 6.0 0.0 3.2 0.4 0.2 0.5 0.7
Cluster #3 0.0 3.5 0.7 1.6 2.8 0.1 0.4 0.2 0.0
Cluster #4 5.0 0.0 18.9 4.4 0.4 4.9 2.4 0.9 3.6
Cluster #5 1.6 2.3 1.2 0.3 1.2 0.0 3.1 0.3 1.5
Cluster #6 1.5 0.6 1.4 1.6 1.3 0.1 0.9 1.6 1.3
Cluster #7 1.9 2.1 1.0 1.2 3.3 2.4 0.6 2.4 0.9
Cluster #8 3.3 3.5 0.0 0.2 2.8 0.1 0.4 3.3 0.9
Cluster #9 0.5 2.8 2.3 0.9 0.0 0.8 1.4 0.0 2.2
Rows and columns indicate hierarchical clustering result and network clustering re-
sult, respectively. A higher NMI percentage implies greater concordance between
clusters.
Table 3.7: Concordance between affinity propagation clustering and network cluster-










Cluster #1 0.5 1.2 3.3 1.2 1.0 2.4 0.6 1.2 3.7
Cluster #2 7.9 0.6 0.5 0.6 0.5 1.2 0.3 0.6 0.5
Cluster #3 1.0 2.5 2.4 2.8 2.4 0.5 5.3 2.8 1.7
Cluster #4 0.0 3.8 0.1 3.6 0.4 0.2 2.0 6.0 0.1
Cluster #5 2.1 0.5 0.1 0.1 0.4 0.9 2.0 0.1 0.6
Cluster #6 0.4 0.0 3.5 4.1 1.4 0.3 0.1 0.0 0.2
Cluster #7 2.4 0.0 6.2 0.6 5.7 0.9 0.2 2.6 1.4
Cluster #8 2.6 0.0 0.2 4.8 0.2 1.8 2.4 2.4 3.2
Cluster #9 1.0 13.0 0.5 0.6 0.5 1.2 0.3 0.6 0.5
Cluster #10 0.1 0.6 3.2 0.5 0.3 0.6 2.0 0.5 2.3
Cluster #11 0.4 1.3 2.0 1.6 2.6 0.0 1.3 2.3 1.9
Rows and columns indicate affinity propagation clustering result and network clus-
tering result, respectively. A higher NMI percentage implies greater concordance
between clusters.
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As a future work, one would need to investigate what factors increase the risk
of developing T1D related complications such as Dyslipidemia and thyroid diseases
since we found clusters enriched with these complications.
3.5 Conclusion
Computational methods are needed to investigate large heterogeneous data and create
a comprehensive view of a biological process such as a diseases developing. We use
Similarity Network Fusion (SNF) to integrate clinical, demographic and genetic data
to aid patients stratification and to distinguish those at a higher risk of developing
T1D complications. We take following steps to achieve this:
1. We impute T1D input dataset to eliminate missing entries and then segment
this dataset into six parts while each segment comprises identical feature types.
2. A sample similarity network is constructed for each of the six sub-datasets.
3. These similarity networks are fused to a single network by applying a nonlinear
integration method.
4. The fused network samples are clustered using the network clustering method.
5. Finally, the obtained clustering result is evaluated with the patients’ compli-
cations information and clusters that are over-enriched with patients having
secondary diseases related to T1D are discussed.
SNF can extract valuable information from even a small number of samples, this
algorithm is robust to noise and can be used with heterogeneous data. According
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to the achieved result, we identified clusters enriched with patients suffering from
Dyslipidemia and thyroid diseases. Consequently, we have taken first steps to identify
groups of patients at higher risk of developing T1D complications. This results can be
taken as the basis to develop a predictive model that can allow patients and health-
care providers to take preemptive steps to reduce the risk of developing T1D related




Diabetes mellitus type 1 also known as type 1 diabetes (T1D) is a disease in which
the body immune system attacks the β-cells. As a result, very little, or no insulin is
released to control the level of glucose in the blood. This research investigates whether
groups of patients at higher risk for developing of complications or secondary disease
related to T1D can be identified by integrating demographic, clinical and genetic
data.
Our dataset is collected from a cohort study regarding the incidence of childhood
T1D on the Avalon Peninsula of Newfoundland, Canada This region has one of the
highest incidences of T1D reported worldwide [62, 63]. The obtained raw T1D dataset
is a heterogeneous dataset, with 27.2% missing values, which has 239 features from
196 patients. We first perform some pre-processing steps on the raw T1D dataset to
extract a pre-processed dataset and a complication matrix. The pre-processes dataset
comprises 153 rows (patients) with 436 features regarding patients’ demographic,
clinical and genetic data. The complications matrix is a binary data with 153 rows
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(patients) and ten columns (complications). It indicates whether a patient is suffering
from the given T1D secondary diseases or not.
We investigate T1D preprocessed dataset using two approaches namely General-
ized Low Rank Modeling (GLRM) and Similarity Network Fusion (SNF), then we
evaluate the methods outcomes to find clusters enriched with patients suffering from
a specific complication. Figure 4.1 illustrates our work-flow.
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Figure 4.1: Research summary diagram
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We use GLRM approach for analyzing our input dataset and to discover patients
subgroups more likely to have a given complication. This framework handles hetero-
geneous datasets, compresses, and de-noises data, and imputes missing records. It
represents high dimensional bulk data into a lower-dimensional space. The framework
output is two matrices: a tall m × k matrix and a wide k × n matrix; where m is
the number of patients, n is the number of features in the input dataset, and k is the
number of latent features produced by GLRM. We name the tall matrix as “concise
data” which represents the original data feature into k new latent features. Next,
we cluster concise data using three clustering methods including k-means clustering,
hierarchical clustering, and affinity propagation clustering. Each clustering result is
then evaluated using the complications matrix to find clusters enriched with a spec-
ified complication. With the GLRM approach, we could identify clusters enriched
with patients suffering from Hyperglycemia, nerve damage, and high blood pressure.
The other used approach is SNF. SNF uses networks of samples as a basis for
data integration. Its algorithm can be wrapped-up into two steps: 1- Construction
of sample similarity network for each data type, 2- Fusing these networks toward
a single similarity network by applying a nonlinear integration method. The driven
fused network comprises both shared and complementary data among all feed sources.
We categorize our T1D pre-processed dataset into six parts (each part consists of
similar data types). Then, we construct a similarity network for each sub-dataset
and use SNF to fuse all these similarity networks into a single network. The fused
network is clustered using network clustering, and then the result is evaluated using
the complications matrix to find clusters enriched with a specified complication. With
the SNF approach, we could identify clusters enriched with patients suffering from
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Hypoglycemia, Dyslipidemia, and thyroid diseases.
As a result of our research, we have taken first steps to identify groups of patients
at higher risk of developing T1D complications. This results could be taken as the
basis to create a predictive model that could allow patients and health-care providers
to take preemptive steps to reduce the risk of developing T1D related complications
based on each patient characteristics. It also could be used by clinical experts to guide
further investigation on T1D. As an extension of this research, other approaches could
also be applied to the same dataset and compare the obtained results.
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This appendix represents a pre-processed T1D dataset features details and their
specification.
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Table A.1: Dataset Features Details




Amount of insulin taken Ordinal Patient Clinical Data Ordinal 1
Most recent urinalysis result Ordinal Patient Clinical Data Ordinal 1
Rate of glucose monitoring Ordinal Patient Clinical Data Ordinal 1
Current health rating Ordinal Patient Clinical Data Ordinal 1
Current rating of diabetes management Ordinal Patient Clinical Data Ordinal 1
Most recent cholesterol/HDL ratio Numeric Patient Clinical Data Quadratic 2
Most recent creatinine Numeric Patient Clinical Data Quadratic 2
Most recent fasting blood glucose Numeric Patient Clinical Data Quadratic 2
Most recent hemoglobin A1C Numeric Patient Clinical Data Quadratic 2
Most recent Microalbumin/Creatinine ratio Numeric Patient Clinical Data Quadratic 2
Most recent thyroid stimulating hormone level Numeric Patient Clinical Data Quadratic 2
Blood glucose if taken at diagnosis Numeric Patient Clinical Data Quadratic 2
ACE inhibitor used Binary Patient Clinical Data Logistic 3
BP meds used? Binary Patient Clinical Data Logistic 3
Statins used? Binary Patient Clinical Data Logistic 3
Gender Binary Patient Clinical Data Logistic 3
Flu vaccinated? Binary Patient Clinical Data Logistic 3
Pneummococcal vaccinated Binary Patient Clinical Data Logistic 3
Exercise regularly Binary Patient Clinical Data Logistic 3
Self reported difficulty with hypoglycemia Binary Patient Clinical Data Logistic 3
On dialysis? Binary Patient Clinical Data Logistic 3
DKA present on diagnosis Binary Patient Clinical Data Logistic 3
Are Ketones in urine Binary Patient Clinical Data Logistic 3
Whether he/she smokes Binary Patient Clinical Data Logistic 3
Weight (lbs) Numeric Patient Demographic Data Quadratic 4
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Table A.1: Dataset Features Details




Height (kg) Numeric Patient Demographic Data Quadratic 4
Date of birth (Age) Numeric Patient Demographic Data Quadratic 4
Date of diagnosis (Age) Numeric Patient Demographic Data Quadratic 4
Relative with T1D (Brother) Binary Relative Clinical Data Logistic 5
Relative with T1D (Sister) Binary Relative Clinical Data Logistic 5
Relative with T1D (Father) Binary Relative Clinical Data Logistic 5
Relative with T1D (Maternal Aunt) Binary Relative Clinical Data Logistic 5
Relative with T1D (Paternal Aunt) Binary Relative Clinical Data Logistic 5
Relative with T1D (Maternal Uncle) Binary Relative Clinical Data Logistic 5
Relative with T1D (Paternal Uncle) Binary Relative Clinical Data Logistic 5
Relative with T1D (Maternal Cousin) Binary Relative Clinical Data Logistic 5
Relative with T1D (Paternal Cousin) Binary Relative Clinical Data Logistic 5
First degree relative has had Lupus Binary Relative Clinical Data Logistic 5
First degree relative has had Thyroid Disease Binary Relative Clinical Data Logistic 5
Crohns disease Complication Binary Relative Clinical Data Logistic 5
Family History of Graves Disease Binary Relative Clinical Data Logistic 5
Family History of Organ Transplantation Binary Relative Clinical Data Logistic 5
Autoimmune disease (Maternal Grandmother) Binary Relative Clinical Data Logistic 5
Autoimmune disease (Maternal Grandfather) Binary Relative Clinical Data Logistic 5
Autoimmune disease (Paternal Grandmother) Binary Relative Clinical Data Logistic 5
Autoimmune disease (Paternal Grandfather) Binary Relative Clinical Data Logistic 5
Parent with MI Binary Relative Clinical Data Logistic 5
Parent with angina Binary Relative Clinical Data Logistic 5
Parent with CVA Binary Relative Clinical Data Logistic 5
Parent with hypertension Binary Relative Clinical Data Logistic 5
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Table A.1: Dataset Features Details




Parent with hyperlipidemia Binary Relative Clinical Data Logistic 5
Parent with PVD Binary Relative Clinical Data Logistic 5
Genetic Marker (95 features) Categorical Patient Genotype Data Categorical 6





This section includes result tables from four clustering approaches used in this report.
PHG indicates hypergeometric test p-value, RR indicates Risk Ratio and OR presents
Odds Ratios. #PCC means number of patients with specified complication in the
cluster. #CLS represents total number of patients in the cluster and #CMP stands
for total number of patients with specified complication.
81
B.1.1 K-means Clustering
Table B.1: k-means clustering results for Thyroid Disease
PHG RR OR Cluster # #PCC #CLS #CMP
1.41E-02 2.84 4.23 5 3 7 25
1.10E-01 1.60 1.80 4 3 12 25
1.63E-01 1.32 1.39 9 12 63 25
4.63E-01 0.89 0.87 6 4 27 25
4.09E-01 0.86 0.84 1 2 14 25
3.87E-01 0.76 0.72 8 1 8 25
4.17E-01 0.00 0.00 2 0 3 25
8.70E-01 0.00 0.00 3 0 11 25
5.14E-01 0.00 0.00 7 0 4 25
5.14E-01 0.00 0.00 10 0 4 25
Table B.2: k-means clustering results for Dyslipidemia
PHG RR OR Cluster # #PCC #CLS #CMP
2.57E-02 2.25 2.96 3 4 11 27
1.49E-01 1.45 1.60 8 2 8 27
1.44E-01 1.43 1.58 10 1 4 27
2.16E-01 1.24 1.31 1 3 14 27
2.74E-01 1.14 1.18 9 12 63 27
5.43E-01 0.81 0.78 6 4 27 27
3.58E-01 0.80 0.77 5 1 7 27
4.44E-01 0.00 0.00 2 0 3 27
9.12E-01 0.00 0.00 4 0 12 27
5.44E-01 0.00 0.00 7 0 4 27
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Table B.3: k-means clustering results for High Blood Pressure
PHG RR OR Cluster # #PCC #CLS #CMP
1.20E-02 2.10 2.65 6 9 27 29
1.63E-01 1.33 1.44 7 1 4 29
1.63E-01 1.33 1.44 10 1 4 29
2.60E-01 1.15 1.19 1 3 14 29
4.05E-01 1.01 1.01 9 12 63 29
3.47E-01 0.96 0.95 3 2 11 29
4.69E-01 0.65 0.60 8 1 8 29
4.70E-01 0.00 0.00 2 0 3 29
9.28E-01 0.00 0.00 4 0 12 29
7.78E-01 0.00 0.00 5 0 7 29
Table B.4: k-means clustering results for Nerve Damage
PHG RR OR Cluster # #PCC #CLS #CMP
4.81E-02 2.66 3.21 7 1 4 15
9.81E-02 1.70 1.82 6 4 27 15
1.43E-01 1.53 1.62 1 2 14 15
1.78E-01 1.29 1.34 8 1 8 15
2.94E-01 0.92 0.91 3 1 11 15
3.33E-01 0.84 0.82 4 1 12 15
6.41E-01 0.71 0.69 9 5 63 15
2.68E-01 0.00 0.00 2 0 3 15
5.22E-01 0.00 0.00 5 0 7 15
3.41E-01 0.00 0.00 10 0 4 15
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Table B.5: k-means clustering results for Retinopathy
PHG RR OR Cluster # #PCC #CLS #CMP
2.06E-02 2.20 3.39 8 4 8 37
2.26E-01 1.20 1.28 1 4 14 37
2.23E-01 1.19 1.27 5 2 7 37
2.59E-01 1.14 1.19 3 3 11 37
2.46E-01 1.03 1.05 7 1 4 37
2.46E-01 1.03 1.05 10 1 4 37
4.95E-01 0.90 0.88 6 6 27 37
6.09E-01 0.87 0.83 9 14 63 37
5.91E-01 0.67 0.61 4 2 12 37
5.67E-01 0.00 0.00 2 0 3 37
Table B.6: k-means clustering results for Diabetic Ketoacidosis
PHG RR OR Cluster # #PCC #CLS #CMP
7.23E-04 3.05 5.91 4 7 12 34
1.53E-02 1.81 2.16 9 19 63 34
1.24E-01 1.52 1.77 2 1 3 34
2.14E-01 1.13 1.17 7 1 4 34
6.42E-01 0.62 0.56 1 2 14 34
9.03E-01 0.45 0.38 6 3 27 34
7.49E-01 0.39 0.33 3 1 11 34
8.35E-01 0.00 0.00 5 0 7 34
8.73E-01 0.00 0.00 8 0 8 34
6.38E-01 0.00 0.00 10 0 4 34
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Table B.7: k-means clustering results for Hyperglycemia
PHG RR OR Cluster # #PCC #CLS #CMP
8.89E-03 2.27 3.55 4 6 12 37
4.41E-02 2.13 3.26 10 2 4 37
2.22E-02 1.68 2.00 9 20 63 37
1.45E-01 1.39 1.58 2 1 3 37
5.24E-01 0.74 0.68 3 2 11 37
8.43E-01 0.57 0.49 6 4 27 37
6.18E-01 0.50 0.43 8 1 8 37
8.98E-01 0.28 0.22 1 1 14 37
8.62E-01 0.00 0.00 5 0 7 37
6.74E-01 0.00 0.00 7 0 4 37
Table B.8: k-means clustering results for Hypoglycemia X
PHG RR OR Cluster # #PCC #CLS #CMP
2.32E-02 2.35 3.02 4 4 12 24
5.20E-02 1.69 1.87 9 13 63 24
1.16E-01 1.62 1.83 7 1 4 24
1.16E-01 1.62 1.83 10 1 4 24
3.02E-01 0.91 0.89 5 1 7 24
6.52E-01 0.67 0.63 6 3 27 24
6.82E-01 0.43 0.39 1 1 14 24
4.03E-01 0.00 0.00 2 0 3 24
8.57E-01 0.00 0.00 3 0 11 24
7.53E-01 0.00 0.00 8 0 8 24
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Table B.9: k-means clustering results for Anxiety
PHG RR OR Cluster # #PCC #CLS #CMP
4.15E-02 2.45 3.04 5 2 7 19
3.23E-02 2.42 2.95 3 3 11 19
7.55E-02 2.07 2.43 7 1 4 19
2.23E-01 1.24 1.29 6 4 27 19
2.42E-01 1.17 1.20 1 2 14 19
7.43E-01 0.66 0.62 9 6 63 19
4.55E-01 0.65 0.62 4 1 12 19
3.30E-01 0.00 0.00 2 0 3 19
6.63E-01 0.00 0.00 8 0 8 19
4.15E-01 0.00 0.00 10 0 4 19
Table B.10: k-means clustering results for Depression
PHG RR OR Cluster # #PCC #CLS #CMP
6.82E-02 2.19 2.59 10 1 4 18
1.23E-01 1.61 1.75 3 2 11 18
1.88E-01 1.33 1.39 6 4 27 18
1.92E-01 1.23 1.26 5 1 7 18
2.87E-01 1.14 1.16 9 8 63 18
4.25E-01 0.69 0.66 4 1 12 18
5.12E-01 0.58 0.55 1 1 14 18
3.15E-01 0.00 0.00 2 0 3 18
3.97E-01 0.00 0.00 7 0 4 18
6.42E-01 0.00 0.00 8 0 8 18
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B.1.2 Hierarchical Clustering
Table B.11: Hierarchical clustering results for Thyroid Disease
PHG RR OR Cluster # #PCC #CLS #CMP
4.16E-02 1.88 2.21 4 6 22 25
1.41E-01 1.47 1.61 1 3 13 25
2.12E-01 1.25 1.32 3 3 15 25
2.13E-01 1.24 1.30 5 6 31 25
1.88E-01 1.23 1.29 6 1 5 25
4.58E-01 0.80 0.77 8 2 15 25
8.04E-01 0.58 0.53 2 4 38 25
4.17E-01 0.00 0.00 7 0 3 25
8.70E-01 0.00 0.00 9 0 11 25
Table B.12: Hierarchical clustering results for Dyslipidemia
PHG RR OR Cluster # #PCC #CLS #CMP
3.87E-02 2.37 3.28 6 2 5 27
3.48E-02 1.78 2.06 2 10 38 27
1.05E-01 1.61 1.84 9 3 11 27
9.81E-02 1.60 1.82 3 4 15 27
5.73E-01 0.74 0.70 4 3 22 27
5.16E-01 0.74 0.70 8 2 15 27
8.52E-01 0.49 0.44 5 3 31 27
9.29E-01 0.00 0.00 1 0 13 27
4.44E-01 0.00 0.00 7 0 3 27
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Table B.13: Hierarchical clustering results for High Blood Pressure
PHG RR OR Cluster # #PCC #CLS #CMP
9.43E-03 2.40 3.33 3 6 15 29
4.73E-02 2.19 2.99 6 2 5 29
3.98E-02 1.92 2.38 8 5 15 29
9.23E-02 1.79 2.18 7 1 3 29
4.34E-01 0.96 0.95 2 7 38 29
4.07E-01 0.95 0.94 4 4 22 29
6.56E-01 0.46 0.41 9 1 11 29
7.50E-01 0.38 0.33 1 1 13 29
9.66E-01 0.29 0.24 5 2 31 29
Table B.14: Hierarchical clustering results for Nerve Damage
PHG RR OR Cluster # #PCC #CLS #CMP
9.47E-04 4.60 6.40 3 5 15 15
4.30E-02 2.30 2.63 8 3 15 15
7.57E-02 2.11 2.39 6 1 5 15
3.59E-01 0.98 0.98 5 3 31 15
2.94E-01 0.92 0.91 9 1 11 15
7.73E-01 0.47 0.44 2 2 38 15
7.53E-01 0.00 0.00 1 0 13 15
9.14E-01 0.00 0.00 4 0 22 15
2.68E-01 0.00 0.00 7 0 3 15
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Table B.15: Hierarchical clustering results for Retinopathy
PHG RR OR Cluster # #PCC #CLS #CMP
9.16E-02 1.69 2.15 6 2 5 37
7.63E-02 1.45 1.66 2 12 38 37
2.57E-01 1.15 1.21 4 6 22 37
2.80E-01 1.12 1.16 3 4 15 37
2.80E-01 1.12 1.16 8 4 15 37
5.24E-01 0.74 0.68 9 2 11 37
6.52E-01 0.62 0.55 1 2 13 37
8.25E-01 0.61 0.54 5 5 31 37
5.67E-01 0.00 0.00 7 0 3 37
Table B.16: Hierarchical clustering results for Diabetic Ketoacidosis
PHG RR OR Cluster # #PCC #CLS #CMP
1.02E-02 3.12 7.38 7 2 3 34
7.31E-02 1.85 2.42 6 2 5 34
1.32E-01 1.44 1.63 1 4 13 34
8.68E-02 1.45 1.63 2 11 38 34
1.05E-01 1.42 1.59 5 9 31 34
4.37E-01 0.89 0.86 3 3 15 34
6.93E-01 0.57 0.51 8 2 15 34
9.79E-01 0.18 0.14 4 1 22 34
9.43E-01 0.00 0.00 9 0 11 34
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Table B.17: Hierarchical clustering results for Hyperglycemia
PHG RR OR Cluster # #PCC #CLS #CMP
1.24E-02 2.61 5.03 6 3 5 37
1.19E-01 1.44 1.66 3 5 15 37
1.45E-01 1.39 1.58 7 1 3 37
1.56E-01 1.28 1.39 2 11 38 37
1.73E-01 1.26 1.37 5 9 31 37
3.87E-01 0.95 0.94 1 3 13 37
5.14E-01 0.81 0.76 8 3 15 37
7.96E-01 0.36 0.29 9 1 11 37
9.87E-01 0.17 0.13 4 1 22 37
Table B.18: Hierarchical clustering results for Hypoglycemia X
PHG RR OR Cluster # #PCC #CLS #CMP
2.77E-02 2.69 3.82 6 2 5 24
2.67E-02 1.97 2.30 5 8 31 24
1.25E-01 1.54 1.70 1 3 13 24
1.90E-01 1.31 1.39 8 3 15 24
4.66E-01 0.85 0.83 4 3 22 24
4.28E-01 0.84 0.81 3 2 15 24
9.01E-01 0.43 0.38 2 3 38 24
4.03E-01 0.00 0.00 7 0 3 24
8.57E-01 0.00 0.00 9 0 11 24
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Table B.19: Hierarchical clustering results for Anxiety
PHG RR OR Cluster # #PCC #CLS #CMP
1.66E-03 5.88 15.65 7 2 3 19
1.40E-02 3.48 5.14 6 2 5 19
1.41E-01 1.52 1.63 9 2 11 19
2.79E-01 1.08 1.10 3 2 15 19
5.35E-01 0.81 0.78 2 4 38 19
5.66E-01 0.74 0.71 5 3 31 19
5.38E-01 0.70 0.67 4 2 22 19
5.00E-01 0.60 0.56 1 1 13 19
5.84E-01 0.51 0.48 8 1 15 19
Table B.20: Hierarchical clustering results for Depression
PHG RR OR Cluster # #PCC #CLS #CMP
1.39E-03 6.25 16.75 7 2 3 18
1.19E-02 3.70 5.50 6 2 5 18
2.50E-01 1.15 1.17 3 2 15 18
2.50E-01 1.15 1.17 8 2 15 18
4.78E-01 0.86 0.85 2 4 38 18
5.17E-01 0.79 0.76 5 3 31 18
3.80E-01 0.76 0.74 9 1 11 18
4.69E-01 0.63 0.60 1 1 13 18
7.72E-01 0.35 0.32 4 1 22 18
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B.1.3 Affinity Propagation Clustering
Table B.21: Affinity Propagation clustering results for Thyroid Disease
PHG RR OR Cluster # #PCC #CLS #CMP
3.51E-02 1.83 2.10 7 9 36 25
1.18E-01 1.52 1.68 5 4 17 25
1.75E-01 1.34 1.43 8 4 19 25
2.06E-01 1.27 1.33 6 4 20 25
4.50E-01 0.67 0.63 11 1 9 25
5.95E-01 0.65 0.61 10 2 18 25
8.09E-01 0.33 0.29 4 1 17 25
4.17E-01 0.00 0.00 1 0 3 25
1.63E-01 0.00 0.00 2 0 1 25
8.92E-01 0.00 0.00 3 0 12 25
1.63E-01 0.00 0.00 9 0 1 25
Table B.22: Affinity Propagation clustering results for Dyslipidemia
PHG RR OR Cluster # #PCC #CLS #CMP
9.15E-03 2.78 4.21 11 4 9 27
1.99E-02 2.14 2.71 10 6 18 27
2.77E-01 1.14 1.17 7 7 36 27
3.57E-01 0.94 0.93 3 2 12 27
4.87E-01 0.83 0.80 6 3 20 27
6.11E-01 0.64 0.59 5 2 17 27
6.94E-01 0.56 0.51 8 2 19 27
8.45E-01 0.31 0.26 4 1 17 27
4.44E-01 0.00 0.00 1 0 3 27
1.76E-01 0.00 0.00 2 0 1 27
1.76E-01 0.00 0.00 9 0 1 27
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Table B.23: Affinity Propagation clustering results for High Blood Pressure
PHG RR OR Cluster # #PCC #CLS #CMP
0.00E+00 5.43 Inf 2 1 1 29
0.00E+00 5.43 Inf 9 1 1 29
6.65E-02 1.85 2.27 11 3 9 29
9.23E-02 1.79 2.18 1 1 3 29
9.51E-02 1.56 1.78 10 5 18 29
2.05E-01 1.24 1.31 7 8 36 29
4.07E-01 0.92 0.91 5 3 17 29
5.05E-01 0.81 0.78 8 3 19 29
5.51E-01 0.77 0.73 6 3 20 29
7.06E-01 0.42 0.37 3 1 12 29
9.78E-01 0.00 0.00 4 0 17 29
Table B.24: Affinity Propagation clustering results for Nerve Damage
PHG RR OR Cluster # #PCC #CLS #CMP
0.00E+00 10.86 Inf 2 1 1 15
2.55E-02 3.57 4.86 1 1 3 15
3.40E-02 2.17 2.40 7 6 36 15
2.50E-01 1.15 1.17 10 2 18 15
2.16E-01 1.14 1.16 11 1 9 15
2.79E-01 1.09 1.10 8 2 19 15
5.18E-01 0.57 0.54 5 1 17 15
6.15E-01 0.48 0.45 6 1 20 15
7.24E-01 0.00 0.00 3 0 12 15
8.44E-01 0.00 0.00 4 0 17 15
9.80E-02 0.00 0.00 9 0 1 15
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Table B.25: Affinity Propagation clustering results for Retinopathy
PHG RR OR Cluster # #PCC #CLS #CMP
0.00E+00 4.22 Inf 2 1 1 37
1.44E-01 1.41 1.62 11 3 9 37
1.45E-01 1.39 1.58 1 1 3 37
1.38E-01 1.37 1.53 8 6 19 37
2.10E-01 1.20 1.28 7 10 36 37
3.22E-01 1.04 1.05 3 3 12 37
3.93E-01 0.97 0.96 5 4 17 37
4.50E-01 0.91 0.88 10 4 18 37
7.67E-01 0.59 0.51 6 3 20 37
8.33E-01 0.46 0.38 4 2 17 37
2.42E-01 0.00 0.00 9 0 1 37
Table B.26: Affinity Propagation clustering results for Diabetic Ketoacidosis
PHG RR OR Cluster # #PCC #CLS #CMP
0.00E+00 4.61 Inf 9 1 1 34
2.63E-02 2.13 3.04 11 4 9 34
1.44E-01 1.38 1.54 4 5 17 34
1.44E-01 1.38 1.54 5 5 17 34
2.63E-01 1.15 1.20 6 5 20 34
2.62E-01 1.14 1.18 3 3 12 34
6.02E-01 0.73 0.67 10 3 18 34
6.51E-01 0.68 0.62 8 3 19 34
8.76E-01 0.56 0.49 7 5 36 34
5.32E-01 0.00 0.00 1 0 3 34
2.22E-01 0.00 0.00 2 0 1 34
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Table B.27: Affinity Propagation clustering results for Hyperglycemia
PHG RR OR Cluster # #PCC #CLS #CMP
0.00E+00 4.22 Inf 9 1 1 37
3.75E-02 1.75 2.23 10 7 18 37
7.99E-02 1.55 1.85 5 6 17 37
1.44E-01 1.41 1.62 11 3 9 37
3.44E-01 1.04 1.05 6 5 20 37
3.93E-01 0.97 0.96 4 4 17 37
6.99E-01 0.76 0.70 7 7 36 37
5.91E-01 0.67 0.61 3 2 12 37
8.89E-01 0.40 0.33 8 2 19 37
5.67E-01 0.00 0.00 1 0 3 37
2.42E-01 0.00 0.00 2 0 1 37
Table B.28: Affinity Propagation clustering results for Hypoglycemia X
PHG RR OR Cluster # #PCC #CLS #CMP
1.02E-01 1.60 1.78 4 4 17 24
1.26E-01 1.50 1.64 10 4 18 24
1.65E-01 1.34 1.42 7 7 36 24
1.81E-01 1.33 1.41 6 4 20 24
5.20E-01 0.73 0.69 5 2 17 24
6.05E-01 0.64 0.60 8 2 19 24
5.92E-01 0.51 0.47 3 1 12 24
4.03E-01 0.00 0.00 1 0 3 24
1.57E-01 0.00 0.00 2 0 1 24
1.57E-01 0.00 0.00 9 0 1 24
7.94E-01 0.00 0.00 11 0 9 24
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Table B.29: Affinity Propagation clustering results for Anxiety
PHG RR OR Cluster # #PCC #CLS #CMP
0.00E+00 8.44 Inf 9 1 1 19
1.46E-02 3.00 4.00 11 3 9 19
4.08E-02 2.78 3.67 1 1 3 19
6.40E-02 1.88 2.12 8 4 19 19
1.73E-01 1.38 1.46 3 2 12 19
3.55E-01 0.94 0.93 4 2 17 19
4.67E-01 0.78 0.76 6 2 20 19
7.02E-01 0.61 0.57 7 3 36 19
6.58E-01 0.44 0.41 5 1 17 19
1.24E-01 0.00 0.00 2 0 1 19
9.21E-01 0.00 0.00 10 0 18 19
Table B.30: Affinity Propagation clustering results for Depression
PHG RR OR Cluster # #PCC #CLS #CMP
0.00E+00 8.94 Inf 9 1 1 18
3.67E-02 2.94 3.91 1 1 3 18
7.34E-02 2.00 2.29 11 2 9 18
1.41E-01 1.50 1.60 10 3 18 18
3.21E-01 1.00 1.00 4 2 17 18
4.22E-01 0.93 0.92 7 4 36 18
4.28E-01 0.83 0.81 6 2 20 18
4.25E-01 0.69 0.66 3 1 12 18
6.26E-01 0.47 0.44 5 1 17 18
6.91E-01 0.41 0.38 8 1 19 18
1.18E-01 0.00 0.00 2 0 1 18
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B.1.4 Network Clustering
Table B.31: Network clustering results for Thyroid Disease
PHG RR OR Cluster # #PCC #CLS #CMP
6.32E-04 3.71 6.42 5 6 12 25
2.77E-02 2.24 2.86 3 4 12 25
2.51E-01 1.17 1.21 2 3 16 25
3.24E-01 1.07 1.08 1 5 29 25
4.58E-01 0.80 0.77 4 2 15 25
7.81E-01 0.60 0.55 6 4 37 25
7.44E-01 0.38 0.34 8 1 15 25
6.64E-01 0.00 0.00 7 0 6 25
8.70E-01 0.00 0.00 9 0 11 25
Table B.32: Network clustering results for Dyslipidemia
PHG RR OR Cluster # #PCC #CLS #CMP
1.14E-04 3.87 7.16 4 8 15 27
1.25E-01 1.49 1.65 2 4 16 27
3.02E-01 1.03 1.04 9 2 11 27
3.57E-01 0.94 0.93 3 2 12 27
3.57E-01 0.94 0.93 5 2 12 27
6.18E-01 0.74 0.70 1 4 29 27
6.87E-01 0.71 0.67 6 5 37 27
6.95E-01 0.00 0.00 7 0 6 27
9.54E-01 0.00 0.00 8 0 15 27
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Table B.33: Network clustering results for High Blood Pressure
PHG RR OR Cluster # #PCC #CLS #CMP
3.98E-02 1.92 2.38 4 5 15 29
5.19E-02 1.88 2.32 5 4 12 29
1.31E-01 1.49 1.67 9 3 11 29
1.70E-01 1.36 1.47 3 3 12 29
3.58E-01 0.99 0.99 2 3 16 29
4.85E-01 0.89 0.87 1 5 29 29
5.88E-01 0.82 0.78 6 6 37 29
7.23E-01 0.00 0.00 7 0 6 29
9.64E-01 0.00 0.00 8 0 15 29
Table B.34: Network clustering results for Nerve Damage
PHG RR OR Cluster # #PCC #CLS #CMP
1.34E-02 3.23 4.06 9 3 11 15
3.98E-02 2.14 2.38 1 5 29 15
9.78E-02 1.81 1.97 3 2 12 15
1.68E-01 1.42 1.48 4 2 15 15
3.33E-01 0.84 0.82 5 1 12 15
4.47E-01 0.66 0.63 8 1 15 15
4.83E-01 0.61 0.59 2 1 16 15
9.88E-01 0.00 0.00 6 0 37 15
4.67E-01 0.00 0.00 7 0 6 15
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Table B.35: Network clustering results for Retinopathy
PHG RR OR Cluster # #PCC #CLS #CMP
4.52E-03 2.50 4.30 9 6 11 37
1.53E-01 1.40 1.60 7 2 6 37
1.17E-01 1.37 1.54 1 9 29 37
2.80E-01 1.12 1.16 4 4 15 37
3.36E-01 1.04 1.05 2 4 16 37
3.22E-01 1.04 1.05 3 3 12 37
5.91E-01 0.67 0.61 5 2 12 37
7.55E-01 0.53 0.45 8 2 15 37
9.40E-01 0.49 0.41 6 5 37 37
Table B.36: Network clustering results for Diabetic Ketoacidosis
PHG RR OR Cluster # #PCC #CLS #CMP
2.63E-02 2.03 2.76 5 5 12 34
2.45E-02 1.97 2.62 8 6 15 34
6.75E-02 1.72 2.13 9 4 11 34
1.11E-01 1.48 1.69 2 5 16 34
2.17E-01 1.23 1.31 4 4 15 34
4.00E-01 0.74 0.69 7 1 6 34
6.72E-01 0.74 0.68 1 5 29 34
9.60E-01 0.42 0.35 6 4 37 34
9.57E-01 0.00 0.00 3 0 12 34
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Table B.37: Network clustering results for Hyperglycemia
PHG RR OR Cluster # #PCC #CLS #CMP
9.39E-02 1.56 1.89 9 4 11 37
1.19E-01 1.44 1.66 4 5 15 37
1.32E-01 1.42 1.64 5 4 12 37
1.17E-01 1.37 1.54 1 9 29 37
5.14E-01 0.81 0.76 8 3 15 37
5.73E-01 0.76 0.70 2 3 16 37
7.34E-01 0.73 0.67 6 7 37 37
4.48E-01 0.68 0.62 7 1 6 37
8.37E-01 0.33 0.27 3 1 12 37
Table B.38: Network clustering results for Hypoglycemia X
PHG RR OR Cluster # #PCC #CLS #CMP
4.23E-03 2.57 3.27 1 9 29 24
9.66E-02 1.68 1.90 5 3 12 24
1.90E-01 1.31 1.39 4 3 15 24
2.38E-01 1.17 1.21 9 2 11 24
7.45E-01 0.63 0.58 6 4 37 24
5.92E-01 0.51 0.47 3 1 12 24
7.21E-01 0.40 0.36 8 1 15 24
7.57E-01 0.37 0.33 2 1 16 24
6.47E-01 0.00 0.00 7 0 6 24
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Table B.39: Network clustering results for Anxiety
PHG RR OR Cluster # #PCC #CLS #CMP
6.03E-03 3.06 3.99 2 5 16 19
1.41E-01 1.52 1.63 9 2 11 19
1.73E-01 1.38 1.46 3 2 12 19
1.73E-01 1.38 1.46 5 2 12 19
2.79E-01 1.08 1.10 4 2 15 19
5.05E-01 0.80 0.78 1 3 29 19
7.26E-01 0.59 0.55 6 3 37 19
5.55E-01 0.00 0.00 7 0 6 19
8.77E-01 0.00 0.00 8 0 15 19
Table B.40: Network clustering results for Depression
PHG RR OR Cluster # #PCC #CLS #CMP
1.82E-02 2.63 3.22 4 4 15 18
2.65E-02 2.58 3.17 9 3 11 18
2.44E-02 2.45 2.93 2 4 16 18
4.25E-01 0.69 0.66 3 1 12 18
4.25E-01 0.69 0.66 5 1 12 18
6.80E-01 0.63 0.59 6 3 37 18
7.07E-01 0.53 0.50 1 2 29 18
5.34E-01 0.00 0.00 7 0 6 18
8.61E-01 0.00 0.00 8 0 15 18
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B.2 Clustering Evaluation p-value
This section includes obtained p-value per clusters for given complications obtained
from four clustering approaches used in this report. p-values less than 0.1 are high-
lighted.
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Thyroid Disease 0.705 1.000 1.000 0.316 0.084 0.680 1.000 0.766 0.294 1.000
Dyslipidemia 0.472 1.000 0.107 1.000 0.742 0.751 1.000 0.424 0.430 0.543
High Blood Pressure 0.510 1.000 0.669 1.000 1.000 0.036 0.579 0.823 0.568 0.573
Nerve Damage 0.415 1.000 0.683 0.729 1.000 0.260 0.343 0.569 0.818 1.000
Retinopathy 0.449 1.000 0.520 0.841 0.532 0.689 0.669 0.097 0.740 0.682
Diabetic Ketoacidosis 0.867 0.534 0.942 0.006 1.000 0.968 0.641 1.000 0.042 1.000
Hyperglycemia 0.984 0.567 0.796 0.041 1.000 0.936 1.000 0.902 0.053 0.245
Hypoglycemia X 0.918 1.000 1.000 0.095 0.699 0.840 0.498 1.000 0.125 0.498
Anxiety 0.547 1.000 0.139 0.814 0.204 0.437 0.415 1.000 0.881 1.000
Depression 0.844 1.000 0.377 0.794 0.591 0.389 1.000 1.000 0.480 0.396
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Thyroid Disease 0.360 0.921 0.459 0.124 0.389 0.590 1.000 0.745 1.000
Dyslipidemia 1.000 0.090 0.260 0.785 0.946 0.209 1.000 0.790 0.304
High Blood Pressure 0.946 0.623 0.041 0.632 0.994 0.237 0.466 0.129 0.910
Nerve Damage 1.000 0.932 0.007 1.000 0.627 0.398 1.000 0.171 0.701
Retinopathy 0.873 0.160 0.514 0.446 0.926 0.344 1.000 0.509 0.794
Diabetic Ketoacidosis 0.323 0.167 0.691 0.998 0.223 0.309 0.120 0.889 1.000
Hyperglycemia 0.650 0.280 0.280 0.999 0.313 0.093 0.570 0.751 0.957
Hypoglycemia X 0.334 0.970 0.717 0.716 0.075 0.173 1.000 0.425 1.000
Anxiety 0.838 0.751 0.587 0.799 0.790 0.115 0.038 0.877 0.401
Depression 0.820 0.706 0.555 0.948 0.747 0.104 0.034 0.568 0.765
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Thyroid Disease 1.000 1.000 1.000 0.958 0.287 0.421 0.090 0.386 1.000 0.838 0.813
Dyslipidemia 1.000 1.000 0.669 0.970 0.851 0.734 0.458 0.886 1.000 0.069 0.052
High Blood Pressure 0.473 0.195 0.926 1.000 0.671 0.783 0.358 0.742 0.189 0.233 0.234
Nerve Damage 0.266 0.102 1.000 1.000 0.843 0.890 0.099 0.594 1.000 0.554 0.623
Retinopathy 0.571 0.248 0.583 0.953 0.630 0.914 0.355 0.291 1.000 0.682 0.372
Diabetic Ketoacidosis 1.000 1.000 0.518 0.312 0.315 0.469 0.950 0.845 0.221 0.814 0.111
Hyperglycemia 1.000 1.000 0.841 0.620 0.195 0.557 0.834 0.974 0.238 0.108 0.382
Hypoglycemia X 1.000 1.000 0.880 0.254 0.782 0.383 0.323 0.836 1.000 0.309 1.000
Anxiety 0.325 1.000 0.454 0.662 0.907 0.752 0.871 0.199 0.129 1.000 0.085
Depression 0.313 1.000 0.789 0.620 0.898 0.717 0.657 0.922 0.120 0.353 0.287
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Thyroid Disease 0.539 0.503 0.110 0.748 0.004 0.910 1.000 0.942 1.000
Dyslipidemia 0.806 0.304 0.657 0.001 0.664 0.839 1.000 1.000 0.616
High Blood Pressure 0.695 0.621 0.399 0.127 0.168 0.764 1.000 1.000 0.343
Nerve Damage 0.122 0.822 0.328 0.454 0.730 1.000 1.000 0.808 0.074
Retinopathy 0.224 0.577 0.593 0.516 0.828 0.980 0.446 0.920 0.023
Diabetic Ketoacidosis 0.830 0.267 1.000 0.439 0.094 0.989 0.787 0.082 0.208
Hyperglycemia 0.238 0.795 0.969 0.276 0.324 0.860 0.813 0.756 0.257
Hypoglycemia X 0.016 0.942 0.880 0.427 0.282 0.895 1.000 0.929 0.527
Anxiety 0.748 0.031 0.452 0.580 0.462 0.891 1.000 1.000 0.396
Depression 0.896 0.105 0.795 0.080 0.785 0.858 1.000 1.000 0.130
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